Next Article in Journal
Pharmacokinetic Enhancers (Boosters)—Escort for Drugs against Degrading Enzymes and Beyond
Previous Article in Journal
Antifibrotic Activity and In Ovo Toxicity Study of Liver-Targeted Curcumin-Gold Nanoparticle
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Sci. Pharm.
Volume 86
Issue 4
10.3390/scipharm86040042
scipharm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Structure-Antibacterial Activity Relationships of N-Substituted-(d-/l-Alaninyl) 1H-1,2,3-Triazolylmethyl Oxazolidinones

by
Oludotun Adebayo Phillips
1,*,
Edet Ekpenyong Udo
2 and
Roselyn Jennifer D’silva
1
1
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait
2
Department of Microbiology, Faculty of Medicine, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait
*
Author to whom correspondence should be addressed.
Sci. Pharm. 2018, 86(4), 42; https://doi.org/10.3390/scipharm86040042
Submission received: 30 August 2018 / Revised: 20 September 2018 / Accepted: 21 September 2018 / Published: 26 September 2018
Browse Figures
Versions Notes

Abstract

:
Bacterial resistance towards the existing class of antibacterial drugs continues to increase, posing a significant threat to the clinical usefulness of these drugs. These increasing and alarming rates of antibacterial resistance development and the decline in the number of new antibacterial drugs’ approval continue to serve as a major impetus for research into the discovery and development of new antibacterial agents. We synthesized a series of d-/l-alaninyl substituted triazolyl oxazolidinone derivatives and evaluated their antibacterial activity against selected standard Gram-positive and Gram-negative bacterial strains. Overall, the compounds showed moderate to strong antibacterial activity. Compounds 9d and 10d (d- and l-alaninyl derivatives bearing the 3,5-dinitrobenzoyl substituent), 10e (l-alaninyl derivative bearing the 5-nitrofurancarbonyl group) and 9f and 10f (d- and l-alaninyl derivatives bearing the 5-nitrothiophene carbonyl moiety) demonstrated antibacterial activity (MIC: 2 µg/mL) against Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis and Moraxella catarrhalis standard bacterial strains. No significant differences were noticeable between the antibacterial activity of the d- and l-alaninyl derivatives as a result of the stereochemistry of the compounds.

Graphical Abstract

1. Introduction

Antibacterial agents are among the successful class of drugs that are effective in treating human infectious diseases with positive clinical outcomes. However, a persistent and significant clinical problem in the fight against bacterial infections is the ever-increasing emergence of bacterial resistance to major classes of antibacterial agents [1,2,3]. Multiply-resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae (PRSP), methicillin-resistant Staphylococcus epidermidis (MRSE), vancomycin-resistant enterococci (VRE) and multidrug-resistant Mycobacterium tuberculosis (MDR-TB) are among the troublesome pathogens within the healthcare and some community settings worldwide [4,5,6,7]. The emergence of antibacterial resistance continues to serve as the impetus for research into novel antibacterial drug discovery and development of more potent and safer antibacterial agents.
Oxazolidinones exemplified by linezolid (1, Figure 1) and more recently tedizolid phosphate (2a, Figure 1), which is a pro-drug of the active form tedizolid (2b, Figure 1), represent derivatives of this class of compounds with potent activity against multidrug-resistant Gram-positive pathogenic bacterial strains [8,9,10]. Linezolid is characterized by excellent oral bioavailability, tissue and organ penetration, with demonstrated effectiveness against multi-drug-resistant Gram-positive bacterial pathogens, including MRSA, PRSP and VRE. Furthermore, it is also active against MDR-TB; hence, it may be useful for treating multi-drug-resistant tuberculosis [8,9,11].
Oxazolidinones inhibit bacterial protein biosynthesis by binding to sites on the bacterial ribosomes, thus preventing the formation of a functional 70S initiation complex [11,12,13]. More detailed studies have investigated the orientation of the oxazolidinone class of compound on the ribosome [14] and Duffy et al. [15] have shown that linezolid binds to the A-site of the 50S subunit, thus preventing binding of the aminoacyl-tRNA.
Several investigators have engaged in structural modifications around the phenyl-oxazolidinone pharmacophore with the hope of discovering newer derivatives with a broader spectrum of activity, to improve potency and to reduce side-effects compared with linezolid. However, linezolid is plagued with a number of undesirable side effects, such as lactic acidosis, myelosuppression, neuropathies and thrombocytopenia during prolonged administration. Furthermore, treatment with linezolid may lead to unfavorable interactions with adrenergic and serotonergic agents, and this may result in severe hypertensive crisis in patients [12,16,17]. Serotonin toxicity has been associated with its inhibitory effects on monoamine oxidases (MAO), due to the structural similarity to the MAO inhibitor toloxatone, which also contains the oxazolidinone moiety. The triazolyl derivatives (3, Figure 1) [18] and the reverse C5 amide derivative of linezolid of a general structure (4, Figure 1) have been shown to exhibit strong antibacterial activity and lower monoamine oxidase inhibition [19]. In addition, Compound 4 also exhibited reduced myelotoxicity in rodents compared to linezolid [20].
Studies from our laboratory and those of others have reported the synthesis of several triazolylmethyl oxazolidinones containing acyl or aroyl-substituted piperazine of the general structures of 5–8 (Figure 1) with potent activity that is comparable or superior to linezolid against Gram-positive bacterial strains including MRSA, VRE, PRSP and MDR-TB [18,21,22,23,24,25,26,27]. Moreover, other studies have also demonstrated that the incorporation of N-substituted-glycinyl moieties on the 4-N-piperazine position resulted in oxazolidinone derivatives that would fit a potential pocket identified at the bacterial ribosomal receptor binding site [27]. The most potent oxazolidinones in the glycinyl series contain the N-nitroaroyl substituents on the glycine nitrogen [23]; in particular, the 3,5-dinitrobenzoyl and the 5-nitrofuroyl derivatives demonstrated MIC values in the range of 0.06–16 µg/mL against Gram-positive bacterial clinical isolates. On the basis of the potent antibacterial activities of the N-substituted glycinyl-triazolyl oxazolidinones, we decided to investigate the effects of incorporating d- and l-alanine as spacers instead of the glycine on the antibacterial activity with focus on the nitro- and amino-substituted aroyl and heteroaroyl derivatives. We hereby report the synthesis and qualitative structure-antibacterial activity relationships of new N-substituted-d- and l-alaninyl-triazolyl oxazolidinone derivatives of the general structures 9a–l and 10a–l, respectively.

2. Materials and Methods.

2.1. Characterization

Purification of compounds was performed with silica gel column chromatography using silica gel (Kieselgel 60, 70–230 mesh; Merck, (formerly Sigma-Aldrich), Germany, and TLC was conducted on 0.25-mm pre-coated silica gel plates (60F254, Merck). Melting points were determined on a Stuart Scientific melting point apparatus (SMP1) (Stuart, Stone, UK) and were uncorrected. Mass spectra were recorded on a Thermo Scientific DFS Gas Chromatography/Mass Spectrometer (DFS GC-MS) (Thermo Fisher Scientific, Bremen, Germany) and Waters QToF high resolution/Mass Spectrometer (LC MS/MS high resolution) (Waters Corporation, Milford, MA, USA). The 1H-NMR and 13C-NMR spectra in DMSO-d6 using solvent peaks as reference signals were recorded on Bruker DPX 400 MHz and Bruker Avance II 600 NMR spectrometers. Chemical shifts of protons and carbons were reported in parts per million (ppm) downfield and upfield from solvent DMSO-d6 (δ = 2.5; 39.7) peaks as references. Infrared (IR) spectra of solids (KBr) were recorded on an FT-IR (Jasco FT/IR-6300) (JASCO, Tokyo, Japan) spectrometer. The Elemental analyses were performed on an Elementar Vario Micro Cube CHN Analyzer (Elementar, Langenselbold, Germany). Elemental analyses (C, H, N) were used to confirm the purity of all newly synthesized compounds (>95%) and indicated by the symbols of the elements within ±0.40% of the theoretical values. Analyses were performed by The General Facilities Science (GF-S), Faculty of Science, Kuwait University, Kuwait.

2.2. Syntheses

2.2.1. Preparation of (R)-5-((1H-1,2,3-triazol-1-yl)methyl)-3-(4-(4-(D-alanyl)piperazin-1-yl)-3-fluorophenyl)oxazolidin-2-one 2,2,2-trifluoroacetate 16a

A solution of (tert-butoxycarbonyl)-D-alanine (1.027 gm, 5.430 mmol) in anhydrous DCM (35 mL) was treated with N, N’-dicyclohexylcarbodiimide (1.40 gm, 6.787 mmol) and 1-hydroxybenzotriazole (0.917 gm, 6.787 mmol), and the mixture was stirred under a nitrogen atmosphere for 2 h. The reaction mixture was filtered directly into a solution of the trifluoro acetate salt, 14 (2.50 gm, 5.430 mmol) and TEA (2.19 mL, 15.747 mmol) in anhydrous CH3CN (40 mL) at 0 °C. The reaction mixture was stirred overnight and concentrated on a rotavap under vacuum to give a viscous oil, which was dissolved in DCM (40 mL), and the precipitated urea was filtered off. The DCM layer was washed with water, 10% Na2CO3 solution, brine, dried (Na2SO4), filtered and concentrated under vacuum to give a brown foam, which was triturated with ether to yield a cream-colored crude solid. This solid was recrystallized from ethyl acetate to afford the carbamate 15a as an off-white solid, 2.07 gm, yield: 74%; mp.: 214–216 °C. 1H-NMR (DMSO-d6, 600 MHZ): δ 8.18 (d, 1H, J = 0.7 Hz, triazole H), 7.77 (d, 1H, J = 0.8 Hz, triazole H), 7.43 (dd, 1H J = 2.5 Hz, 14.7 Hz, phenyl H), 7.14 (dd, 1H, J = 2.3 Hz, 8.8 Hz, phenyl H), 7.07 (t, 1H, J = 9.3 Hz, phenyl H), 6.96 (d, 1H, NH, J = 7.9 Hz, exchangeable with D2O), 5.12-5.14 (m, 1H, oxazolidinone H), 4.83 (d, 2H, J = 5.1 Hz, CH2), 4.45–4.50 (m, 1H, d-alanine CH), 4.21 (t, 1H, J = 9.2 Hz, oxazolidione H), 3.87 (q, 1H, J = 5.8 Hz, 9.3 Hz, oxazolidinone H), 3.59–3.66 (br. d, 4H, piperazine H), 2.96 (br. d, 4H, piperazine H), 1.36–1.38 (br., 9H, C(CH3)3), 1.17 (d, 3H, J = 6.9 Hz, CH3)). 13C-NMR (DMSO-d6): δ 171.2, 155.8, 155.3, 154.2, 153.9, 135.8, 133.9, 133.8, 133.7, 126.3, 120.2, 120.2, 114.8, 114.7, 107.3, 107.1, 78.4, 71.3, 52.2, 51.1, 50.8, 47.6, 46.3, 45.2, 42.0, 28.7, 18.2. IR (KBr pellet, cm−1): ν 3328, 3185, 3125, 2929, 2792, 1738, 1628, 1574, 1536, 1386, 1311, 1271, 1462, 1244, 1185, 1088, 1047. LRMS (m/z): 517.3 (M+), HRMS (m/z): calcd. for C24H32FN7O5: 517.2449; found 540.2400 (M+ + Na). Anal. calcd. for C24H32FN7O5: C: 55.70, H: 6.23, N: 18.94; found C: 55.75, H: 6.56, N: 18.41.
A solution of 15a (6.07 g, 11.73 mmol) in DCM (12.0 mL) was treated with trifluoroacetic acid (12.0 mL) and stirred to room temperature overnight. The reaction mixture was concentrated to dryness to give a brown oil, which was digested several times with ether and treated with THF/diethyl ether (1:1 mixture) with stirring to give 16a as a cream-colored solid, 4.92 g, yield: 79%. This solid was utilized for subsequent reactions without further purification. 1H-NMR (DMSO-d6, 600 MHZ): δ 8.17 (d, 1H, J = 0.7 Hz, triazole H), 8.13 (br. d, 3H, J = 3.8 Hz, +NH3, exchangeable with D2O), 7.76 (d, 1H, J = 0.8 Hz, triazole H), 7.42 (dd, 1H, J = 2.5 Hz, 14.7 Hz, phenyl H), 7.12 (dd, 2H, J = 2.3 Hz, 8.8 Hz, phenyl H), 7.07 (t, 1H, J = 9.3 Hz, phenyl H), 5.10–5.14 (m, 1H, oxazolidinone H), 4.83 (d, 1H, J = 5.0 Hz, CH2), 4.42–4.44 (m, 1H, d-alanine CH), 4.22 (t, 1H, J = 9.2 Hz, oxazolidinone H), 3.86 (q, 1H, J = 5.8 Hz, 9.3 Hz, oxazolidinone H), 3.56–3.79 (m, 4H, piperazine H), 2.91–3.03 (m, 4H, piperazine H), 1.33 (d, 3H, J = 7.0 Hz, CH3)). 13C-NMR (DMSO-d6, 600 MHZ): δ 168.0, 158.5, 158.3, 158.1, 157.9, 155.4, 153.8, 153.5, 135.2, 135.2, 135.2, 133.5, 133.4, 125.9, 119.9, 119.8, 117.5, 115.6, 114.6, 113.6, 106.9, 106.7, 70.8, 51.7, 50.5, 50.1, 47.1, 45.9, 44.8, 41.7, 16.4. LRMS (m/z): calcd. for C19H24FN7O3 (M+ − CF3O2H): 417.30. HRMS (m/z): calcd. for C21H25F4N7O5: 531.1853; found 530.2300 (M+ − H).

2.2.2. Preparation of (R)-5-((1H-1,2,3-triazol-1-yl)methyl)-3-(4-(4-(L-alanyl)piperazin-1-yl)-3-fluorophenyl) oxazolidin-2-one 2,2,2-trifluoroacetate 16b

Compound 16b was prepared via a similar procedure to the D-alaninyl isomer 16a from (tert-butoxycarbonyl)-L-alanine (0.410 gm, 2.172 mmol), N,N′-dicyclohexyl carbodiimide (0.560 gm, 2.715 mmol), 1-hydroxy -benzotriazole (0.366 gm, 2.715 mmol), TFA salt (1.00 gm, 2.172 mmol) and TEA (0.877 mL, 6.30 mmol) in a mixture of DCM (40 mL) and acetonitrile (15 mL) and worked up in a similar manner to give the intermediate compound 15b as an off-white solid, 0.913 g, yield: 82%; recrystallized (EtOAc), mp.: 203–207 °C. 1H-NMR (DMSO-d6, 600 MHZ): δ 8.18 (d, 1H, J = 0.7 Hz, triazole H), 7.77 (d, 1H, J = 0.8 Hz, triazole H), 7.43 (dd, 1H, J = 2.5 Hz, 14.4 Hz, phenyl H), 7.28 (dd,1H, J = 2.3 Hz, 8.8 Hz, phenyl H), 7.06 (t, 1H, J = 9.3 Hz, phenyl H), 7.00 (br. d, 1H, J = 7.9 Hz, NH, exchangeable with D2O), 5.09–5.15 (m, 1H, oxazolidinone H), 4.83 (d, 2H, J = 5.1 Hz, CH2), 4.45–4.50 (m, 1H, l-alanine CH), 4.21 (t, 1H, J = 9.2 Hz, oxazolidinone H), 3.87 (q, 1H, J = 5.7 Hz, 9.3 Hz, oxazolidinone H), 3.63–3.65 (br. d, 4H, piperazine H), 2.91–2.98 (br. d, 4H, piperazine H), 1.36 (br d, 9H, (CH3)3), 1.16 (d, 3H, J = 6.9 Hz, CH3). 13C-NMR (DMSO-d6, 600 MHZ): δ 170.7, 155.3, 154.8, 153.7, 153.4, 135.4, 135.3, 133.3, 133.3, 133.2, 125.8, 119.7, 114.2, 106.8, 106.7, 77.9, 70.7, 51.7, 50.6, 50.3, 47.1, 45.8, 44.7, 41.5, 28.2, 17.7. IR (KBr pellet, cm−1): ν 3634, 3500, 3346, 3121, 2980, 2900, 2811, 2722, 1877, 1736, 1653, 1578, 1520, 1447, 1387, 1367, 1280, 1236, 1120, 1061, 1028. LRMS (m/z): 517.3 (M+). Calcd. for C24H32FN7O5: 517.2449; found 540.2500 (M+ + Na). Anal. calcd. for C24H32FN7O5: C: 55.70, H: 6.23, N: 18.94; found C: 55.21, H: 6.31, N: 18.55.
Compound 16b was prepared via a similar procedure to 16a from a solution of 15b (8.0 g, 15.46 mmol) in DCM (16.0 mL) in trifluoroacetic acid (16.0 mL) to afford the title compound as a cream solid, 7.36 g, yield: 90%. This solid was utilized for subsequent reactions without further purification. 1H-NMR (DMSO-d6, 600 MHZ): δ 8.17 (d, 1H, J = 0.7 Hz, triazole H), 8.12 (br. d, 3H, J = 4.0 Hz, +NH3, exchangeable with D2O), 7.76 (d, 1H, J = 0.7 Hz, triazole H), 7.42 (dd, 1H, J = 2.5 Hz, 14.7 Hz, phenyl H), 7.14 (dd, 2H, J = 2.3 Hz, 8.8 Hz, phenyl H), 7.07 (t, 1H, J = 9.3 Hz, phenyl H), 5.11–5.14 (m, 1H, oxazolidinone H), 4.83 (d, 1H, J = 5.0 Hz, CH2), 4.41–4.44 (m, 1H, l-alanine CH), 4.21 (t, 1H, J = 9.1 Hz, oxazolidinone H), 3.86 (q, 1H, J = 5.7 Hz, 9.3 Hz, oxazolidinone H), 3.59–3.67 (m, 4H, piperazine H, overlaps with DOH signal), 2.90–3.08 (m, 4H, piperazine H), 1.33 (d, 3H, J = 7.0 Hz, CH3). 13C-NMR (DMSO-d6, 600 MHZ): δ 167.9, 158.0, 157.8, 155.4, 153.8, 153.5, 135.2, 135.2, 133.4, 133.3, 125.9, 119.8, 119.8, 116.1, 114.3, 114.3, 106.9, 106.7, 70.7, 51.7, 50.4, 50.1, 47.1, 45.9, 44.7, 41.6, 16.4. LRMS (m/z): calcd. for C19H24FN7O3 (M+ − CF3O2H): 417.3. HRMS (m/z): calcd. for C21H25F4N7O5: 531.1853; found 530.2400 (M+ − H).

2.2.3. Preparation of N-((R)-1-(4-(4-((R)-5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperazin-1-yl)-1-oxopropan-2-yl)-2-nitrobenzamide 9a

To an ice-cooled solution of 16a (0.700 g, 1.317 mmol) in anhyd. CH3CN (20 mL) was added TEA (0.70 mL) and 2-nitrobenzoyl chloride (0.363 g, 1.97 mmol), and the reaction mixture was stirred overnight. The reaction mixture was diluted with DCM (100 mL), washed with water (3 × 80 mL), 10% NaHCO3 solution (80 mL), water (80 mL) and brine (80 mL), dried (Na2SO4), filtered and concentrated to give a yellow solid, which was triturated with ether and filtered to give a yellow solid, 0.580 g, recrystallized (CH3CN) to give the title Compound 9a as a yellow solid, 190 mg, yield: 23%; mp.: 124–126 °C. 1H-NMR (DMSO-d6, 600 MHZ):δ 9.03 (d, 1H, NH, J = 8.0 Hz), 8.17 (d,1H, J = 0.7 Hz, triazole H), 8.03 (dd, 1H, J = 0.9 Hz, 8.1 Hz, nitrobenzene H), 7.79 (t, 1H, J = 7.1 Hz, nitrobenzene H), 7.76 (d, 1H, J = 1.0 Hz, triazole H), 7.66–7.77 (m, 1H, nitrobenzene H), 7.61 (dd, 1H, J = 1.3 Hz, 7.6 Hz, nitrobenzene H), 7.42 (dd,1H, J = 3.4 Hz, 12.1 Hz, phenyl H), 7.27 (dd, 1H, J = 2.3 Hz, 8.8 Hz, phenyl H), 7.06 (t, 1H, J = 7.5 Hz, phenyl H), 5.09–5.14 (m, 1H oxazolidinone H), 4.94–4.95 (m, 1H, d-alanine CH), 4.83 (d, 2H, J = 5.2 Hz, CH2), 4.20 (t,1H, J = 9.0 Hz, oxazolidinone), 3.87 (dd, 1H, J = 5.3 Hz, 8.9 Hz, oxazolidinone CH), 3.74–3.61 (m, 4H, piperazine H), 3.03–2.93 (m, 4H, piperazine H), 1.29 (d, 3H, J = 6.8 Hz, CH3). 13C-NMR (DMSO-d6, 600 MHZ): δ 167.9, 163.1, 153.7, 152.1, 151.8, 145.3, 133.8, 133.7, 131.9, 133.7, 131.7, 131.6, 130.5, 129.1, 127.6, 124.2, 122.4, 118.1, 118.1, 112.6, 112.6, 105.2, 105.0, 69.1, 50.1, 49.1, 48.6, 45.4, 43.3, 43.2, 40.0, 15.7. IR (KBr pellet, cm−1): 3305, 3112, 1753, 1645, 1519, 1282, 1228, 1026, 743. LRMS (m/z) 566.5 (M+). Anal. calcd. for C26H27FN8O6: C: 55.12, H: 4.80, N: 19.78; found C: 55.1, H: 5.21, N: 19.65.

2.2.4. Preparation of N-((S)-1-(4-(4-((R)-(5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperazin-1-yl)-1-oxopropan-2-yl)-2-nitrobenzamide 10a

Compound 10a was prepared via a similar procedure to 9a from 16b (0.90 g, 1.693 mmol) and 2-nitrobenzoyl chloride (0.471 gm, 2.54 mmol) to give 10a as a yellow solid, 258 mg, yield: 27%; recrystallized (CH3CN), mp.: 185–190 °C. 1H-NMR (DMSO-d6, 600 MHZ): δ 9.05 (d, NH, 1H, J = 8.0 Hz, exchangeable with D2O), 8.17 (s, 1H, triazole H), 8.05 (dd, 1H, J = 0.5 Hz, 8.2 Hz, nitrobenzene H), 7.79–7.82 (m, 1H, nitrobenzene H), 7.77 (s, 1H, triazole H), 7.69–7.72 (m, 1H, nitrobenzene H), 7.62 (dd, 1H, J = 1.1 Hz, 7.6 Hz, nitrobenzene H), 7.44 (dd, 1H, J = 2.4 Hz, 14.7 Hz, phenyl H), 7.14 (dd, 1H, J = 2.3 Hz, 8.8 Hz, phenyl H), 7.07 (t, 1H, J = 9.3 Hz, phenyl H), 5.11–5.15 (m, 1H, oxazolidinone H), 4.96–5.01 (m, 1H, l-alanine CH), 4.84 (d, 2H, J = 5.1, CH2), 4.22 (t, 1H, J = 9.2 Hz, oxazolidinone H), 3.87 (dd, 1H, J = 5.7 Hz, 9.3 Hz, oxazolidinone H), 3.60–3.80 (m, 4H, piperazine H), 2.90–3.06 (m, 4H, piperazine H), 1.30 (d, 3H, J = 6.8 Hz, CH3). 13C-NMR (DMSO-d6, 600 MHZ): δ 175.4, 169.4, 158.9, 158.7, 154.3, 144.8, 140.6, 140.6, 138.6, 134.3, 131.1, 128.7, 125.0, 119.6, 112.1, 111.9, 84.8, 84.5, 84.3, 76.1, 57.0, 55.9, 55.5, 52.4, 50.8, 50.2, 46.9, 22.5. IR (KBr pellet, cm−1): ν 3309, 3122, 2826, 1729, 1635, 1601, 1524, 1442, 1341, 1228, 1160, 1118, 1028. LRMS (m/z) 566.2 (M+). Anal. calcd. for C26H27FN8O6: C: 55.12, H: 4.80, N: 19.78; found C: 54.98, H: 5.22, N: 19.70.

2.2.5. Preparation of N-((R)-1-(4-(4-((R)-5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperazin-1-yl)-1-oxopropan-2-yl)-3-nitrobenzamide 9b

Compound 9b was prepared via a similar procedure to 9a from 16a (0.700 g, 1.317 mmol) and 3-nitrobenzoyl chloride (0.363 g, 1.97 mmol) to give a yellow solid, 0.580 g, yield: 68%; recrystallized (CH3CN), mp.: 208–210 °C. 1H-NMR (DMSO-d6, 600 MHZ): δ 9.13 (d, NH, 1H, J = 7.4 Hz, exchangeable with D2O), 8.75 (t, 1H, J = 1.9 Hz, nitrobenzene H), 8.38–8.40 (m, 1H, nitrobenzene H), 8.33–8.35 (m, 1H, nitrobenzene H), 8.17 (d, 1H, J = 0.8 Hz, triazole H), 7.79 (t, 1H, J = 8.0 Hz, nitrobenzene H), 7.77 (d, 1H, J = 0.7 Hz, triazole H), 7.42 (dd, 1H, J = 2.5 Hz, 14.7 Hz, phenyl H), 7.12 (dd, 1H, J = 3.8 Hz, 9.4 Hz, phenyl H), 7.06 (t, 1H, J = 9.3 Hz, phenyl H), 5.11–5.14 (m, 1H, oxazolidinone H), 4.98–5.05 (m, 1H, d-alanine CH), 4.83 (d, 2H, J = 5.1 Hz, CH2), 4.21 (t, 1H, J = 9.2 Hz, oxazolidinone H), 3.86 (dd, 1H, J = 5.7 Hz, 9.3 Hz, oxazolidinone H), 3.62–3.70 (m, 4H, piperazine H), 2.95–3.01 (br. d, 4H, piperazine H), 1.35 (d, 3H, J = 7.0 Hz, CH3). 13C-NMR (DMSO-d6, 600 MHZ): δ 170.7, 164.2, 155.8, 154.2, 153.9, 148.2, 135.9, 135.8, 135.8, 134.5, 133.9, 133.8, 133.7, 130.6, 126.5, 126.3, 122.7, 120.3, 120.2, 114.7, 114.7, 107.3, 107.1, 71.3, 52.2, 51.1, 50.8, 47.6, 45.9, 45.4, 42.1, 17.7. IR (KBr pellet, cm−1): 3288, 3117, 2823, 1720, 1637, 1517, 1445, 1349, 1285, 1228. LRMS (m/z): 566.6 (M+). Anal. calcd. for C26H27FN8O6: C: 55.12, H: 4.80, N: 19.78; found: C: 54.91, H: 4.71, N: 19.79.

2.2.6. Preparation of N-((S)-1-(4-(4-((R)-(5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperazin-1-yl)-1-oxopropan-2-yl)-3-nitrobenzamide 10b

Compound 10b was prepared via a similar procedure to 9a from 16b (0.90 g, 1.693 mmol) and 3-nitrobenzoyl chloride (0.471 g, 2.54 mmol) to give a cream-colored solid, 480 mg, yield: 51%; recrystallized (EtOAc), mp.: 138–145 °C. 1H-NMR (DMSO-d6, 600 MHZ): δ 9.13 (d, NH, 1H, J = 7.4 Hz, exchangeable with D2O), 8.75 (t, 1H, J = 1.9 Hz, nitrobenzene H), 8.38–8.40 (m, 1H, nitrobenzene H), 8.33–8.35 (m, 1H, nitrobenzene H), 8.16 (d, 1H, J = 0.7 Hz, triazole H), 7.78 (t, 1H, J = 8.0 Hz, nitrobenzenene H), 7.76 (d, 1H, J = 0.7 Hz, triazole H), 7.42 (dd, 1H, J = 2.5 Hz, 14.7 Hz, phenyl H), 7.13 (dd, 1H, J = 3.8 Hz, 9.4 Hz, phenyl H), 7.06 (t, 1H, J = 9.3 Hz, phenyl H), 5.10–5.14 (m, 1H, oxazolidinone H), 5.01–5.05 (m, 1H, l-alanine CH), 4.83 (d, 2H, J = 5.1 Hz, CH2), 4.20 (t, 1H, J = 11.8 Hz, oxazolidinone H), 3.86 (dd, 1H, J = 5.7 Hz, 9.3 Hz, oxazolidinone H), 3.62–3.70 (m, 4H, piperazine H), 2.95–3.01 (br. d, 4H, piperazine H), 1.35 (d, 3H, J = 7.0 Hz, CH3). 13C-NMR (DMSO-d6, 600 MHZ): δ 175.4, 168.9, 160.6, 159, 158.7, 153, 140.7, 140.6, 140.5, 139.2, 138.6, 138.6, 138.5, 135.3, 131.3, 131.1, 127.5, 125.0, 119.5, 112.1, 112.9, 76.0, 56.9, 55.9, 55.6, 52.3, 50.7, 50.2, 46.9, 22.5, 19.3. IR (KBr pellet, cm−1): ν 3442, 3309, 3122, 2826, 1729, 1635, 1600, 1523, 1442, 1419, 1340, 1227, 1200, 1160, 1118, 1028. LRMS (m/z): 566.4 (M+). Anal. calcd. for C26H27FN8O6: C: 55.12, H: 4.80, N: 19.78; found C: 55.16, H: 4.88, N: 19.91.

2.2.7. Preparation of N-((R)-1-(4-(4-((R)-5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperazin-1-yl)-1-oxopropan-2-yl)-4-nitrobenzamide 9c

Compound 9c was prepared via a similar procedure to 9a from 16a (0.700 g, 1.317 mmol) and 4-nitrobenzoyl chloride to give a yellow solid, 300 mg, yield: 38%, recrystallized (CH3CN); mp.: 228–230 °C. 1H-NMR (DMSO-d6, 600 MHZ) δ: 9.04 (d, 1H, J = 9 Hz, NH, exchangeable with D2O), 8.32 (d, 2H, J = 8.9 Hz, phenyl H), 8.16 (d, 1H, J = 0.8 Hz, triazole H), 8.12 (d, 2H, J = 8.9 Hz, phenyl H), 7.76 (d, 1H, J = 0.8 Hz, triazole H), 7.42 (dd, 1H, J = 2.9 Hz, 15.7 Hz, phenyl H), 7.13 (dd, 1H, J = 3.5 Hz, 8.3 Hz, phenyl H), 7.06 (t, 1H, J = 9.6 Hz, phenyl H), 5.10–5.15 (m, 1H, oxazolidinone H), 4.99–5.04 (m, 1H, d-alanine CH), 4.83 (d, 2H, J = 5.1 Hz, CH2), 4.20 (t, 1H, J = 9.2 Hz, oxazolidinone H), 3.86 (dd, 1H, J = 5.5 Hz, 8.3 Hz, oxazolidinone H), 3.58–3.75 (m, 4H, piperazine H), 2.90–3.06 (m, 4H, piperazine H), 1.34 (d, 3H, J = 7.0 Hz, CH3). 13C-NMR (DMSO-d6, 600 MHZ): δ 170.6, 164.7, 155.8, 154.2, 153.9, 149.6, 140.0, 135.9, 135.8, 133.9, 133.8, 133.7, 129.5, 126.3, 123.9, 120.3, 120.2, 114.7, 107.3, 107.1, 71.3, 52.2, 51.1, 50.8, 47.6, 45.9, 45.4, 42.1, 17.7. IR (KBr pellet, cm−1): 3373, 2821, 1742, 1640, 1529, 1444, 1341, 1226, 1162, 1110, 1028. LRMS (m/z): 566.5 (M+). Anal. calcd. for C26H27FN8O6: C: 55.12, H: 4.80, N: 19.78; found: C: 54.73, H: 5.00, N: 20.06.

2.2.8. Preparation of N-((S)-1-(4-(4-((R)-(5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperazin-1-yl)-1-oxopropan-2-yl)-4-nitrobenzamide 10c

Compound 10c was prepared via a similar procedure to 9a from 16b (0.90 g, 1.693 mmol) and 4-nitrobenzoyl chloride (0.471 g, 2.54 mmol) to afford a yellow solid, 450 mg, yield: 47%, recrystallized (CH3CN), mp.: 245–247 °C. 1H-NMR (DMSO-d6, 600 MHZ): δ 9.06 (d, NH, 1H, J = 7.4, NH, exchangeable with D2O), 8.33 (d, 2H, J = 8.9 Hz, nitrobenzene H), 8.18 (d, 1H, J = 0.7 Hz, triazole H), 8.13 (d, 2H, J = 8.9 Hz, nitrobenzene H), 7.77 (s, 1H, triazole H), 7.43 (dd, 1H, J = 3.0 Hz, 14.2 Hz, phenyl H), 7.13 (dd, 1H, J = 3.5 Hz, 8.3 Hz, phenyl H), 7.07 (t, 1H, J = 8.9, phenyl H), 5.10–5.16 (m, 1H, oxazolidinone H), 4.98–5.18 (m, 1H, l-alanine CH), 4.84 (d, 2H, J = 5.1 Hz, CH2), 4.21 (t, 1H, J = 8.9, oxazolidinone H), 3.87 (dd, 1H, J = 6.2 Hz, 10.1 Hz, oxazolidinone H), 3.58–3.76 (m, 4H, piperazine H), 2.92–3.08 (m, 4H, piperazine H), 1.35 (d, 3H, J = 7.0, CH3). 13C-NMR (DMSO-d6, 600 MHZ): δ 170.6, 164.7, 155.8, 154.2, 154.0, 149.6, 140.1, 135.9, 135.8, 133.9, 133.8, 133.7, 129.5, 126.3, 124.0, 120.3, 120.3, 114.8, 107.3, 107.2, 71.3, 52.2, 51.1, 50.8, 47.6, 45.9, 45.4, 42.1, 17.7. IR (KBr pellet, cm−1): ν 3439, 3309, 3123, 2826, 1728, 1635, 1601, 1525, 1442, 1341, 1282, 1228, 1200, 1161, 1118, 1028. LRMS (m/z) 566.3 (M+). Anal. calcd. for C26H27FN8O6: C: 55.12, H: 4.80, N: 19.78; found C: 54.95, H: 5.20, N: 19.69.

2.2.9. Preparation of N-((R)-1-(4-(4-((R)-5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperazin-1-yl)-1-oxopropan-2-yl)-3,5-dinitrobenzamide 9d

Compound 9d was prepared via a similar procedure to 9a from 16a (1.00 g, 1.881 mmol) and 3,5-dinitrobenzoyl chloride (0.65 g, 2.82 mmol) to give a yellow solid, 390 mg, yield: 32%, purified by silica gel column chromatography (EtOAc-Hex 10-1, EtOAc and EtOAc-MeOH 10:1)], mp.: 223–225 °C. 1H-NMR (DMSO-d6, 600 MHZ): δ 9.52 (d, 1H, J = 8.8 Hz, NH, exchangeable with D2O), δ 9.13 (d, 2H, J = 2.1 Hz, nitrobenzene H), 8.96 (t, 1H, J = 2.1 Hz, nitrobenzene H), 8.16 (d, 1H, J = 1.0 Hz, triazole H), 7.76 (d, 1H, J = 0.8 Hz, triazole H), 7.42 (d, 1H, J = 3.0 Hz, 14.2 Hz, phenyl H), 7.13 (d, 1H, J = 3.5 Hz, 8.3 Hz, phenyl H), 7.07 (t, 1H, J = 11.1Hz, phenyl H), 5.02–5.14 (m, 2H, oxazolidinone H and d-alanine CH), 4.83 (d, 2H, J = 5.0 Hz, CH2), 4.2 (t, 1H, J = 10.7 Hz, oxazolidinone H), 3.87 (dd, 1H, J = 6.2 Hz, 10.1 Hz, oxazolidinone H), 3.60–3.78 (m, 4H, piperazine H), 2.96–3.08 (m, 4H, piperazine H), 1.38 (d, 3H, J = 7.0 Hz, CH3). 13C-NMR (DMSO-d6, 600 MHZ): δ 170.4, 162.2, 155.8, 154.2, 153.9, 148.7, 136.9, 135.9, 135.8, 133.9, 133.8, 133.7, 128.3, 126.3, 121.5, 120.3, 120.3, 114.8, 114.7, 107.3, 107.1, 71.3, 67.5, 65.4, 60.2, 52.2, 51.1, 50.8, 47.6, 46.2, 45.6, 42.1, 17.7. IR (KBr pellet, cm−1): ν 3481, 3276, 3094.23, 1756, 1633, 1542, 1517, 1445, 1346, 1230, 1028. HRMS (m/z): calcd. for C26H26FN9O8: 611.1888, found 612.20 (M+ + H), LRMS (m/z) 611.5 (M+). Anal. CHN, calcd.: C: 51.06, H: 4.29, N: 20.61; found: C: 49.95, H: 4.70, N: 20.12.

2.2.10. Preparation of N-((S)-1-(4-(4-((R)-5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluoro phenyl)piperazin-1-yl)-1-oxopropan-2-yl)-3,5-dinitrobenzamide 10d

Compound 10d was prepared via a similar procedure to 9a from 16b (0.700 g, 1.317 mmol) and 3,5-dinitro benzoyl chloride (0.455 g, 1.976 mmol) to give a yellow solid, 382 mg, yield: 45%, recrystallization (CH3CN), mp.: 191–194 °C. 1H-NMR (DMSO-d6, 400 MHZ): δ 9.53 (d, 1H, J = 7.2 Hz, NH, exchangeable with D2O), 9.12 (d, 2H, J = 2.0 Hz, nitrobenzene H), 8.96 (t, 1H, J = 2.0 Hz, nitrobenzene H), 8.16 (s, 1H, triazole H), 7.76 (s, 1H, triazole H), 7.42 (dd, 1H, J = 2.2 Hz, 14.7 Hz, phenyl H), 7.06–7.14 (m, 2H, phenyl H), 5.05–5.12 (m, 2H, oxazolidinone H and l-alanine CH), 4.82 (d, 2H, J = 5.0 Hz, CH2), 4.20 (t, 1H, J = 9.1 Hz, oxazolidinone H), 3.85 (dd, 1H, J = 5.7 Hz, 9.3 Hz, oxazolidinone H), 3.64–3.72 (m, 4H, piperazine H), 2.95–3.01 (m, 4H, piperazine H), 1.37 (d, 3H, J = 6.9 Hz, CH3). 13C-NMR (DMSO-d6, 400 Hz): δ 170, 161.8, 153.5, 148.2, 136.4, 135.4, 135.3, 133.4, 133.2, 127.8, 125.9, 121.0, 119.8, 114.3, 107.3, 107.1, 70.8, 51.7, 50.7, 50.3, 47.1, 45.7, 45.0, 42.4, 17.2. IR (KBr pellet, cm−1): ν 3425, 3278, 3109, 1752, 1668, 1631, 1541, 1518, 1484, 1446, 1345, 1230, 1028. HRMS (m/z): calcd. for C26H26FN9O8: 611.1888, found 612.2090 (M+ + H), LRMS (m/z) 611.4 (M+). Anal. CHN, expected: C: 51.06, H: 4.29, N: 20.61, found C: 50.72, H: 4.25, N: 19.61.

2.2.11. Preparation of N-(R)-1-(4-(4-((R)-(5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperazin-1-yl)-1-oxopropan-2-yl)-5-nitrofuran-2-carboxamide 9e

To a stirred solution of 5-nitrofuran-2-carboxylic acid (1.77 gm, 11.288 mmol) in anhyd. DCM (30 mL) cooled in an ice bath was added oxalyl chloride (2.46 mL, 28.22 mmol) under nitrogen followed by 2 drops of dry DMF, and effervescence ensued. The ice bath was removed, and the reaction mixture was stirred 2 h. The mixture was evaporated to dryness on a rotavap to give the acid chloride as a yellow semisolid, which was dried under vacuum. The resulting acid chloride was dissolved in anhyd. DCM (30 mL) and added in rapid drops to a solution of the TFA salt 16a (1.5 g, 2.822 mmol) and TEA (2.14 mL, 11.288 mmol) in CH3CN (32 mL) with cooling in an ice bath. The reaction mixture was left to stir to room temperature overnight under nitrogen and concentrated to dryness. The residue was dissolved in DCM and washed with water, 10% Na2CO3 solution, water, brine and dried with Na2SO4, filtered and concentrated to give a brown foam, which was triturated with ether and hexane (1:1) to afford 9e as a brown solid, 624 mg, yield: 40%, recrystallized (EtOAc), mp.: 180–185 °C. 1H-NMR (DMSO-d6, 600 MHZ): δ 9.08 (d, 1H, J = 8.7 Hz, NH, exchangeable with D2O), 8.18 (d, 1H, J = 0.7 Hz, triazole H), 7.77 (d, 1H, J = 0.7 Hz, triazole H), 7.76 (d, J = 3.9 Hz, nitrofuran H), 7.55 (d, 1H, J = 5.3 Hz, nitrofuran H), 7.43 (dd, 1H, J = 3.7 Hz, 15.0 Hz, phenyl H), 7.14 (dd, 1H, J = 3.7 Hz, 8.0 Hz, phenyl H), 7.08 (t, 1H, J = 7.7 Hz, phenyl H), 5.14–5.12 (m, 1H, oxazolidinone H), 4.97–5.01 (m, 1H, d-alanine CH), 4.83 (d, 2H, J = 6.7 Hz, CH2), 4.21 (t, 1H, J = 9.2 Hz, oxazolidinone H), 3.85–3.88 (q, 1H, J = 4.0 Hz, 8.7 Hz, oxazolidinone H), 3.62–3.71 (m, 4H, piperazine H), 3.00 (m, 4H, piperazine H), 1.34 (d, 3H, J = 6.9 Hz, CH3). IR (KBr pellet, cm−1): ν 3403, 3131, 2929, 2811, 1753, 1642, 1590, 1548, 1521, 1444, 1386, 1350, 1233, 1157, 1113, 1023. LRMS (m/z): 556.5 (M+). Anal. calcd. for C24H25FN8O7: C: 51.80, H: 4.53, N: 20.14; found: C: 51.97, H: 4.26, N: 20.36.

2.2.12. Preparation of N-((S)-1-(4-(4-((R)-(5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxo oxazolidin-3-yl)-2-fluorophenyl)piperazin-1-yl)-1-oxopropan-2-yl)-5-nitrofuran-2-carboxamide 10e

Compound 10e was prepared via a similar procedure to 9e from 16b (0.700 g, 1.317 mmol) and 5-nitrofuran-2-carboxylic acid (0.827 g, 5.268mmol) to give a yellowish-brown solid, 356 mg, yield 46%, recrystallized (CH3CN/MeOH), mp.: 218–222 °C. 1H-NMR (DMSO-d6, 600 MHZ): δ 9.09 (d, 1H, J = 7.5 Hz, NH, exchangeable with D2O), 8.18 (d, 1H, J = 0.7 Hz, triazole H), 7.78 (d, 1H, J = 0.7 Hz, triazole H), 7.77 (d, 1H, J = 3.8 Hz, nitrofuran H), 7.44 (d, 1H, J = 3.8 Hz, nitrofuran H), 7.42 (d, 1H, J = 2.5 Hz, phenyl H), 7.13 (d, 1H, J = 2.3 Hz, phenyl H), 7.08 (t, 1H, J = 9.4 Hz, phenyl H), 5.12–5.14 (m, 1H, oxazolidinone H), 4.98–5.02 (m, 1H, l-alanine CH), 4.84 (d, 1H, J = 5.0, CH2), 4.21 (t, 1H, J = 9.3 Hz, oxazolidinone H), 3.85–3.88 (q, 1H, J = 4.0 Hz, 8.7 Hz, oxazolidinone H), 3.60–3.74 (m, 4H, piperazine H), 2.93–3.06 (m, 4H, piperazine H), 1.34 (d, 3H, J = 7.0 Hz, CH3). 13C-NMR (DMSO-d6, 400 Hz): δ 169.7, 155.5, 155.3, 153.7, 153.4, 147.7, 135.3, 135.3, 133.3, 133.3, 133.2, 125.8, 119.8, 119.8, 115.9, 114.3, 113.3, 106.8, 106.7, 70.7, 51.7, 50.6, 50.2, 47.1, 45, 44.9, 41.7, 17.3. IR (KBr pellet, cm−1): ν 3396, 3351, 3107, 2917, 2823, 1748, 1637, 1542, 1488, 1445, 1421, 1381, 1342, 1276, 11648, 1105, 1074, 1029. LRMS (m/z): 556.5 (M+). HRMS (m/z): calcd. for C24H25FN8O7: 556.1830, found 579.1700 (M+ + Na). Anal. calcd. for C24H25FN8O7: C: 51.80, H: 4.53, N: 20.14, found: C: 51.41, H: 4.78, N: 20.44.

2.2.13. Preparation of N-((R)-1-(4-(4-((R)-(5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl) piperazin-1-yl)-1-oxopropan-2-yl)-5-nitrothiophene-2-carboxamide 9f

Compound 9f was prepared via a similar procedure to 9e from 16a (1.00 g, 1.881 mmol) and 5-nitrothiophene-2-carboxylic acid (1.302 g (7.524 mmol) to give an off-white solid, 262 mg, yield: 24%, recrystallized (CH3CN), mp.: 223–227 °C. 1H-NMR (DMSO-d6, 600 MHZ): 9.27 (d, NH,1 H, J = 7.4 Hz, exchangeable with D2O), 8.17 (d, 1H, J = 0.5 Hz, triazole H), 8.15 (d, nitrothiophene, J = 4.3 Hz, 1H, nitrothiophene H), 7.95 (d, 1H, J = 4.4 Hz, nitrothiophene H), 7.77 (s, 1H, triazole H), 7.43 (dd, 1H, J = 2.4 Hz, 14.7 Hz, phenyl H), 7.27 (dd, 1H, J = 8.8 Hz, 2.3 Hz, phenyl H), 7.07 (t, 1H, J = 9.4 Hz, phenyl H), 5.12–5.14 (m, 1H, oxazolidinone H), 4.97–5.01 (m, 1H, d-alanine CH), 4.83 (d, 1H, J = 5.0 Hz, CH2), 4.21 (t, 1H, J = 9.1 Hz, oxazolidinone H), 3.87 (dd, 1H, J = 5.7 Hz, 9.3 Hz, CH), δ 3.58–3.70 (m, 4H, piperazine H), 2.90–3.05 (m, 4H, piperazine H), 1.34 (d, 3H, J = 7.0 Hz, CH3). 13C-NMR (DMSO-d6): δ 159.5, 155.8, 154.2, 154.0, 153.5, 146.3, 135.8, 133.9, 133.8, 133.7, 130.7, 128.4, 126.3, 120.3, 114.8, 107.3, 107.2, 71.3, 52.2, 51.1, 50.8, 47.6, 46, 45.4, 42.1, 17.7. IR (KBr pellet, cm−1): ν 3396, 3351, 3107, 2917, 2823, 1748, 1637, 1542, 1488, 1445, 1421, 1381, 1342, 1276, 1164, 1105, 1074, 1029. MS: 572.5 (M+). HRMS (m/z): calcd. for C24H25FN8O7S: 572.1602, found 573.1700 (M+ + H), LRMS (m/z): 572.5 (M+). Anal. calcd. for C24H25FN8O6S: C: 49.91, H: 4.57, N: 19.54.; found C: 50.35, H: 4.40, N: 19.57.

2.2.14. Preparation of N-((S)-1-(4-(4-((R)-(5-((1H-1,2,3-triazol-1-yl) methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl) piperazin-1-yl)-1-oxopropan-2-yl)-5-nitrothiophene-2-carboxamide 10f

Compound 10f was prepared via a similar procedure to 9e from 16b (0.700 g, 1.317 mmol) and 5-nitrothiophene-2-carboxylic acid (0.912 g, 5.268 mmol) to give a yellowish-brown solid, 560 mg, yield: 76%, recrystallized (EtOAc), mp.: 211–214 °C. 1H-NMR (DMSO-d6, 600 MHZ): δ 9.27 (d, 1H, J = 7.4 Hz, NH, exchangeable with D2O), 8.18 (d, 1H, J = 0.6 Hz, triazole H), 8.16 (d, 1H, J = 4.4 Hz, nitrothiophene H), 7.98 (d, 1H, J = 4.4 Hz, nitrothiophene H), 7.78 (s, 1H, triazole H), 7.43 (dd, 1H, J = 2.4 Hz, 14.7 Hz, phenyl H), 7.27 (dd, 1H, J = 2.3 Hz, 8.8 Hz, phenyl H), 7.07 (t, 1H, J = 9.4 Hz, phenyl H), 5.11–5.15 (m, 1H, oxazolidinone H), 4.96–5.01 (m, 1H, l-alanine CH), 4.83 (d, 1H, J = 5.0 Hz, CH2), 4.21 (t, 1H, J = 9.4 Hz, oxazolidinone H), 3.87 (dd, 1H, J = 5.3 Hz, 8.9 Hz, oxazolidinone H), 3.56–3.76 (m, 4H, piperazine H), 2.90–3.06 (m, 4H, piperazine H), 1.34 (d, 3H, J = 7.0 Hz, CH3). 13C-NMR (DMSO-d6): δ 169.8, 159.1, 155.4, 153.8, 153.5, 153.1, 145.8, 135.4 135.3, 133.4, 133.3, 133.3, 130.2, 128, 125.9, 119.8, 114.3, 106.8, 106.7, 70.8, 51.7, 50.6, 50.3, 47.1, 45.5, 45.0, 41.7, 17.2. IR (KBr pellet, cm−1): 3425, 3296, 3079, 2918, 2843, 1742, 1643, 1553, 1517, 1424, 1336, 1276, 1228, 1030. LRMS (m/z) 572.5 (M+). HRMS (m/z): calcd. for C24H25FN8O6S (M+): 572.1602, found 573.1800 (M+ + H). Anal. calcd. for C24H25FN8O6S C: 50.35, H: 4.40, N: 19.57, found C: 50.36, H: 4.52, N: 19.20.

2.2.15. Preparation of N-(R)-1-(4-(4-((R)-5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperazin-1-yl)-1-oxopropan-2-yl)-2-nitrobenzenesulfonamide 9g

Compound 9g was prepared via a similar procedure to 9a from 16a (650 mg, 1.222 mmol), TEA (0.650 mL) and 2-nitrobenzenesulfonyl chloride (406 mg, 1.834 mmol) in anhyd. CH3CN (15 mL) to give a yellow solid, 200 mg, yield: 20%, recrystallized (CH3CN), mp.: 128–130 °C. 1H-NMR (DMSO-d6, 600 MHZ): δ 8.33 (br. s,1H, NH exchangeable with D2O), 8.17 (d, 1H, J = 0.7 Hz, triazole H), 8.01–8.03 (m, 1H, nitrobenzene H), 7.94–7.96 (m, 1H, nitrobenzene H), 7.83–7.86 (m, 2H, nitrobenzene H), 7.77 (d, 1H, J = 0.7 Hz, triazole H), 7.41 (dd, 1H, J = 2.6 Hz, 14.7 Hz, phenyl H), 7.13 (dd, 1H, J = 2.4 Hz, J = 8.4 Hz, phenyl H), 7.02 (t, 1H, J = 9.5 Hz, phenyl H), 5.10–5.14 (m, 1H oxazolidinone H), 4.83 (d, 2H, J = 5.1 Hz, CH2), 4.48 (q, 1H, J = 6.8 Hz, d-alanine CH), 4.20 (t, 1H, J = 8.9 Hz, oxazolidinone H), 3.86 (q, 1H, J = 5.7 Hz, 9.3 Hz, oxazolidinone H), 3.60–3.37 (m, 4H, piperazine H), 2.67–2.97 (m, 4H, piperazine H), 1.22 (d, 3H, J = 7.0 Hz, CH3). 13C-NMR (DMSO-d6, 600 MHZ): δ 169.4, 155.8, 154.2, 153.9, 147.8, 135.8, 135.7, 134.5, 133.9, 133.8, 133.6, 133.0, 130.4, 126.3, 124.7, 120.2, 120.2, 114.8, 114.7, 107.3, 107.1, 71.3, 52.2, 50.9, 50.5, 49.1, 47.6, 45.3, 42.0, 19.4. IR (KBr pellet, cm−1): ν 3446, 3303, 3100, 2829, 1752, 1650, 1541, 1518, 1483, 1444, 1417, 1356, 1330, 1233, 1170, 1123, 1028. LRMS (m/z): 602.5 (M+). Anal. calcd. for C25H27FN8O7S: C: 49.83, H: 4.52, N: 18.60; found: C: 49.48, H: 4.73, N: 18.80.

2.2.16. Preparation of N-((S)-1-(4-(4-((R)-(5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl) piperazin-1-yl)-1-oxopropan-2-yl)-2-nitrobenzene sulfonamide 10g

Compound 10g was prepared via a similar procedure to 9a from 16b (700 mg, 1.317 mmol) and 2-nitrobenzenesulfonyl chloride (4–6 mg, 1.834 mmol), to give a yellow solid, 265 mg, yield 30%, recrystallized (CH3CN), mp.: 78–80 °C. 1H-NMR (DMSO-d6, 400 MHZ): δ 8.30 (br., 1H, NH, exchangeable with D2O), 8.16 (s, 1H, triazole H), 8.00–8.03 (m, 1H, nitrobenzene H), 7.93–7.96 (m, 1H, nitrobenzene H), 7.82–7.85 (m, 2H, nitrobenzene H), 7.76 (s, 1H, triazole H), 7.41 (dd, 1H, J = 2.4 Hz, 14.7 Hz, phenyl H), 7.13 (dd, 1H, J = 2.0 Hz, 8.7 Hz, phenyl H), 7.02 (t, 1H, J = 9.3 Hz, phenyl H), 5.09–5.15 (m, 1H, oxazolidinone H), 4.82 (d, 2H, J = 5.0 Hz, CH2), 4.48 (q, 1H, J = 6.8 Hz, l-alanine CH), 4.20 (t, 1H, J = 9.2 Hz, oxazolidinone H), 3.85 (dd, 1H, J = 5.7 Hz, 9.3 Hz, oxazolidinone H), 3.45–3.63 (m, 4H, piperazine H), 2.80–2.96 (m, 4H, piperazine H), 1.21 (m, 3H, J = 6.9 Hz, CH3). IR (KBr pellet, cm−1): ν 3446, 3287, 3130, 2984, 2903, 2827, 1756, 1647, 1542, 1517, 1481, 1442, 1417, 1371, 1230, 1169, 1121, 1028. HRMS (m/z): calcd. for C25H27FN8O7S: 602.1707, found 603.1812 (M+ + H), LRMS (m/z) 602.4 (M+). Anal. calcd. for C25H27FN9O7S: C: 49.83, H: 4.52, N: 18.6; found C: 49.36, H: 4.72, N: 18.34

2.2.17. Preparation of N-((R)-1-(4-(4-((R)-5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl) piperazin-1-yl)-1-oxopropan-2-yl)-3-nitrobenzenesulfonamide 9h

Compound 9h was prepared via a similar procedure to 9a from 16a (660 mg, 1.241 mmol) and 3-nitrobenzenesulfonyl chloride (412 mg, 1.862 mmol) to give a yellow solid, which was triturated with ether and filtered to give a yellow solid, 300 mg, 40% yield, recrystallized (CH3CN); mp.: 115–118 °C. 1H-NMR (DMSO-d6, 600 MHZ): δ 8.45–8.52 (m, 3H, nitrobenzene H and NH, exchangeable with D2O), 8.18–8.20 (m, 1H, nitrobenzene H), 8.17 (s, 1H, triazole H), 7.88 (t, 1H, J = 8.01 Hz, phenyl H) 7.76 (s, 1H, triazole H), 7.42 (dd, 1H, J = 2.5 Hz, 14.7 Hz, phenyl H), 7.14 (dd, 1H, J = 2.3 Hz, 8.8 Hz, phenyl H), 7.00 (t, 1H, J = 9.3 Hz, phenyl H), 5.11–5.14 (m, 1H oxazolidinone H), 4.83 (d, 2H, CH2), 4.44–4.50 (br., 1H, d-alanine CH), 4.20 (t, 1H, J = 9.2 Hz, oxazolidinone H), 3.86 (dd, 1H, J = 5.7 Hz, 9.3 Hz, oxazolidinone H), 3.36–3.64 (m, 2H, piperazine H), 3.28–3.38 (m, 2H, piperazine H, overlaps with DOH signal), 2.58–2.96 (m, 4H, piperazine H), 1.12 (d, 3H, J = 6.9 Hz, CH3). 13C-NMR (DMSO-d6): δ 169.3, 155.8, 154.2, 153.9, 148.1, 143.3, 135.7, 135.7, 133.9, 133.8, 133.3, 131.5, 127.4, 126.3, 122.0, 120.2, 120.2, 114.7, 107.3, 107.1, 71.3, 52.2, 51.1, 50.4, 48.7, 47.6, 45.2, 41.8, 19.2. IR (KBr pellet, cm−1): ν 3149, 3102, 2828, 1756, 1645, 1524, 1422, 1351, 1230, 1167, 1121, 1079, 1027. LRMS (m/z): 602.5. Anal. calcd. for C25H27FN9O7S: C: 49.83, H: 4.52, N: 18.6; found C: 49.55, H: 4.85, N: 18.68.

2.2.18. Preparation of N-((S)-1-(4-(4-((R)-5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl) piperazin-1-yl)-1-oxopropan-2-yl)-3-nitrobenzamide 10h

Compound 10h was prepared via a similar procedure to 9a from 16b (700 mg, 1.317 mmol) and 3-nitrobenzenesulfonyl chloride (437 mg, 1.975 mmol) to give a yellow solid, 180 mg, yield 23%, recrystallized (EtOAc); mp.: 108–110 °C. 1H-NMR (DMSO-d6, 600 MHZ): δ 8.52 (t, 1H, J = 2.0 Hz, nitrobenzene H), 8.46-–8.48 (m, 2H, nitrobenzene H and of NH; the NH broad peak is exchangeable with D2O), 8.20–8.21 (m, 1H, nitrobenzene H), 8.18 (d, 1H, J = 0.8 Hz, triazole H), 7.89 (t, 1H, J = 8.0 Hz, nitrobenzene H), 7.78 (d, 1H, J = 0.8 Hz, triazole H), 7.43 (dd, 1H, J = 2.6 Hz, 14.7 Hz, phenyl H), 7.15 (dd, 1H, J = 2.6 Hz, 8.7 Hz, phenyl H), 7.02 (t, 1H, J = 9.3 Hz, phenyl H), 5.12–5.15 (m, 1H, oxazolidinone H), 4.84 (d, 2H, J = 5.2 Hz, CH2), 4.47–4.50 (m, 1H, l-alanine CH), 4.22 (t, 1H, J = 9.2 Hz, oxazolidinone H), 3.87 (dd, 1H, J = 5.7 Hz, 9.3 Hz, oxazolidinone H), 3.55–3.67 (m, 2H, piperazine H), 3.33–3.403 (m, 2H, piperazine H, overlaps with DOH signal), 2.80–2.98 (m, 3H, piperazine H), 2.62 (br., 1H, piperazine H), 1.13 (d, 3H, J = 6.9 Hz, CH3). 13C-NMR (DMSO-d6, 600 MHZ): δ 155.8, 154.0, 148.1, 133.9, 133.3, 131.5, 126.3, 122.0, 120.2, 114.7, 107.3, 107.1, 71.3, 65.4, 52.2, 51.1, 47.6, 45.2, 41.8, 19.2. IR (KBr pellet, cm−1): ν 3449, 3271, 3150, 2895, 1754, 1645, 1518, 1442, 1421, 1352, 1229, 1169, 1124, 1028. LRMS (m/z) 602.5 (M+). Anal. calcd. for C25H27FN9O7S: C: 49.83, H: 4.52, N: 18.60; found: C: 49.38, H: 4.85, N: 18.74.

2.2.19. Preparation of N-((R)-1-(4-(4-((R)-5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl) piperazin-1-yl)-1-oxopropan-2-yl)-4-nitrobenzenesulfonamide 9i

Compound 10h was prepared via a similar procedure to 9a from 16a (600 mg, 1.128 mmol) and 4-nitrobenzenesulfonyl chloride (374 mg, 1.862 mmol) to give a yellow solid, 200 mg, yield: 29%, recrystallized (CH3CN); mp.: 190–192 °C. 1H-NMR (DMSO-d6, 600 MHZ):δ 8.49 (br., 1H, NH, exchangeable with D2O), 8.38–8.40 (m, 2H, nitrobenzene H), 8.17 (d, 1H, J = 0.7 Hz, triazole H), 8.00–8.04 (m, 2H, nitrobenzene H), 7.77 (s, 1H, J = 0.7 Hz, triazole H), 7.42 (dd, 1H, J = 2.5 Hz, 14.7 Hz, phenyl H), 7.13 (dd, 1H, J = 2.6 Hz, 8.7 Hz, phenyl H), 7.02 (t, 1H, J = 9.5 Hz, phenyl H), 5.11–5.14 (m, 1H, oxazolidinone H), 4.83 (d, 2H, J = 5.0 Hz, CH2), 4.45–4.48 (m, 1H, d-alanine CH), 4.21 (t, 1H, J = 9.2 Hz, oxazolidinone H), 3.86 (dd, 1H, J = 5.5 Hz, 9.1 Hz, oxazolidinone H), 3.57–3.65 (m, 2H, piperazine H), 3.38–3.41 (m, 2H, piperazine H, overlaps with the DOH signal, 2.83–2.94 (m, 3H, piperazine H), 2.67–2.71 (br., 1H, piperazine H), 1.11(d, 3H, J = 6.8 Hz, CH3). 13C-NMR (DMSO-d6, 600 MHZ): δ 169.2, 153.7, 152.1, 151.8, 147.8, 145.1, 133.6, 133.6, 131.7, 131.7, 126.6, 124.2, 122.6, 118.1, 118.1, 112.6, 112.6, 105.2, 105.0, 69.1, 50.1, 48.9, 48.3, 46.5, 45.4, 43.1, 39.7, 17.1. IR (KBr pellet, cm−1): ν 3268, 3102, 2833, 1747, 1643, 1525, 1426, 1347, 1317, 1228, 1165, 1027. LRMS (m/z) 602.4 (M+). Anal. calcd. for C25H27FN9O7S: C: 49.83, H: 4.52, N: 18.6; found: C: 49.47, H: 4.46, N: 18.4

2.2.20. Preparation of N-((S)-1-(4-(4-((R)-(5-((1H-1,2,3-triazol-1-yl) methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl) piperazin-1-yl)-1-oxopropan-2-yl)-4-nitrobenzene sulfonamide 10i

Compound 10l was prepared via a similar procedure to 9a from 16b (700 mg, 1.317 mmol) and 4-nitrobenzenesulfonyl chloride (437 mg, 1.975 mmol) to give a yellow solid, 411 mg, yield 52%, recrystallized (EtOAc); mp.: 203–205 °C. 1H-NMR (DMSO-d6, 400 MHZ): δ 8.48 (br., 1H, NH, exchangeable with D2O), 8.39 (d, 2H, J = 8.8 Hz, nitrobenzene H), 8.16 (s, 1H, triazole H), 8.02 (d, 2H, J = 8.8 Hz, nitrobenzene H), 7.76 (s, 1H, triazole H), 7.41 (dd, 1H, J = 2.4 Hz, 14.8 Hz, phenyl H), 7.14 (dd, 1H, J = 2.1 Hz, 8.5 Hz, phenyl H), 7.02 (t, 1H, J = 9.3 Hz, phenyl H), 5.10–5.14 (m, 1H, oxazolidinone H), 4.82 (d, 2H, J = 5.1 Hz, CH2), 4.40–4.50 (m, 1H, l-alanine CH), 4.20 (t, 1H, J = 9.1 Hz, oxazolidinone H), 3.86 (d, 1H, J = 5.7 Hz, 9.3 Hz, oxazolidinone H), 3.54–3.60 (m, 2H, piperazine H), 3.33 (m, 2H, piperazine H overlaps with DOH signal), 2.83–3.04 (br., 4H, piperazine H), 1.10 (d, 3H, J = 6.9 Hz, CH3). 13C-NMR (DMSO-d6, 600 MHZ): δ 169.9, 155.3, 153.7, 153.4, 149.4, 146.7, 135.2, 135.2, 133.3, 133.3, 128.2, 125.8, 124.2, 119.7, 119.7, 114.2, 106.8, 106.6, 70.7, 51.7, 50.5, 49.9, 48.1, 47.1, 44.7, 41.3, 18.7. HRMS (m/z): calcd. for C25H27FN8O7S: 602.1707, found 603.1912 (M+ + H), LRMS (m/z) 602.4 (M+). IR (KBr pellet, cm−1): ν 3452, 3279, 3102, 1732, 1649, 1520, 1424, 1352, 1310, 1228, 1196, 1168, 1078, 1042, 1026. Anal. calcd. for C25H27FN9O7S: C: 49.83, H: 4.52, N: 18.6; found C: 49.7, H: 4.704, N: 18.4.

2.2.21. Preparation of N-((R)-1-(4-(4-((R)-5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperazin-1-yl)-1-oxopropan-2-yl)-2-aminobenzamide 2,2,2-trifluoroacetate 9j

An ice cooled solution of 2-((tert-butoxycarbonyl) amino-benzoic acid (0.446 gm, 1.881 mmol) in anhyd. DCM (40 mL) was treated with N, N′-dicyclohexylcarbodiimide (485 mg, 2.351 mmol) and 1-hydroxybenzotriazole (318 mg, 6.787 mmol), respectively, and the reaction mixture was stirred for 2 h under nitrogen. The reaction mixture was then filtered into a solution of the TFA salt 16a (1.00 g, 1.881 mmol) and TEA (0.760 mL, 5.45 mmol) in anhyd. CH3CN (15 mL) and left stirring at room temperature overnight. The reaction mixture was concentrated to give a crude brown oil, which was dissolved in DCM, washed with water, 10% Na2CO3 solution, brine, dried Na2SO4, filtered and concentrated to yield a cream-colored solid. The solid was triturated with ether, collected by filtration and recrystallized from ethyl acetate to give the intermediate compound carbamate 17a as a solid, 507 mg, yield 43%; mp.: 188–191 °C. This product was utilized for subsequent reactions. 1H-NMR (DMSO-d6, 600 MHZ): δ 10.45 (s, 1H, NH, exchangeable with D2O), 8.89 (d, 1H, J = 7.3 Hz, NH, exchangeable with D2O), 8.19 (d, 1H, J = 10.1 Hz, phenyl H), 8.17 (d, 1H, J = 0.9 Hz, triazole H), 7.81 (dd, 1H, J = 1.4 Hz, 7.9 Hz, phenyl H), 7.77 (d, 1H, J = 0.8 Hz, triazole H), 7.48 (t, 1H, J = 7.1 Hz, phenyl H), 7.43 (dd, 1H, J = 2.4 Hz, 15.4 Hz, phenyl H), 7.04–7.15 (m, 3H, phenyl H), 5.11–5.15 (m, 1H, oxazolidinone H), 4.95–5.00 (m, 1H, d-alanine CH), 4.83 (d, 2H, J = 5.0 Hz, CH2), 4.21 (t, 1H, J = 8.2 Hz, oxazolidinone H), 3.86 (dd, 1H, J = 5.5 Hz, 9.1 Hz, oxazolidinone H), 3.60–3.78 (m, 4H, piperazine H), 2.94–3.04 (m, 4H, piperazine H), 1.45 (s, 9H, (CH3)3), 1.34 (d, 3H, J = 7.0 Hz, CH3). MS 636.8 (M+). 13C-NMR (DMSO-d6, 400 MHZ): δ 170.2, 167.8, 155.8, 153.5, 153.4, 152.1, 139.4, 135.4, 135.4, 133.4, 133.3, 132.2, 128.6, 125.9, 121.4, 119.8, 119.3, 118.5, 114.3, 106.9, 82.8, 79.8, 70.8, 51.7, 50.3, 47.1, 45.3, 44.9, 41.7, 27.9. IR (KBr pellet, cm−1): ν 3350, 3116, 2978, 2931, 1758, 1718, 1647, 1587, 1520, 1442, 1227, 1159, 1089, 1026. LRMS (m/z): 536.4 (M+ − (CH3)2C=CH2 + CO2). Anal. calcd. for C31H37FN8O6: C: 58.48, H: 5.86, N: 17.18, found C: 58.36, H: 6.19, N: 17.18.
Compound 9j was prepared via a similar procedure to 16a from the intermediate 17a (372 mg, 0.70 mmol) to give a white solid, 157 mg, yield 28%; recrystallized (EtOAc); mp.: 106–109 °C. 1H-NMR (DMSO-d6, 600 MHZ): δ 8.40 (d, 1H, J = 7.4 Hz, NH, exchangeable with D2O), 8.18 (d, 1H, J = 0.7 Hz, triazole H), 7.78 (s, 1H, J = 0.6 Hz, triazole H), 7.60 (d, 1H, J = 7.0 Hz, aminobenzene H), 7.43 (dd, 1H, J = 2.5 Hz, 14.7 Hz, phenyl H), 7.18 (t, 1H, J = 14.7 Hz, aminobenzene H), 7.14 (dd, 1H, J = 2.3 Hz, 8.8 Hz, phenyl H), 7.07 (t, 1H, J = 9.3 Hz, phenyl H), 6.75 (d, 1H, J = 8.2 Hz, aminobenzene H), 6.59 (t, 1H, J = 7.5 Hz, aminobenzene H), 5.11–5.14 (m, 1H, oxazolidinone H), 4.90–4.97 (m, 1H, d-alanine CH), 4.84 (d, 2H, J = 5.0 Hz, CH2), 4.21 (t, 1H, J = 9.2 Hz, oxazolidinone H), 3.87 (dd, 1H, J = 5.7 Hz, 9.3 Hz, oxazolidinone H, overlapping with +NH3 signal), 3.60–3.71 (br. m, 7H, piperazine H, overlapping with +NH3 signal, which is exchangeable with D2O), 2.95–3.01 (br. d, 4H, J = 7.0 Hz, piperazine H), 1.31 (s, 3H, J = Hz, CH3). 13C-NMR (DMSO-d6, 600 MHZ): δ 170.6, 168.1, 158.3, 158.0, 155.4, 153.7, 153.5, 135.4, 135.4, 133.4, 133.3, 133.2, 131.8, 128.5, 125.9, 119.8, 119.7, 116.8, 115.4, 115.1, 114.3, 114.3, 106.8, 106.7, 70.8, 64.9, 51.7, 50.7, 50.3, 47.1, 44.9, 44.7, 41.6, 17.4, 15.2. IR (KBr pellet, cm−1): ν 3447, 3354, 2981, 2829, 1755, 1635, 1517, 1446, 1326, 1230, 1200, 1162, 1027. HRMS (m/z): for C28H30F4N8O6: 650.2224, found 650.0167.

2.2.22. Preparation of N-(R)-1-(4-(4-((R)-5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperazin-1-yl)-1-oxopropan-2-yl)-3-aminobenzamide 2,2,2-trifluoroacetate 9k

Compound 9k was prepared via a similar procedure to 9j from 3-((tert-butoxycarbonyl) amino benzoic acid and 16a (1.00 g, 1.881 mmol) to give the intermediate compound 17b as a white solid, 314 mg, yield 26%, recrystallized (EtOAc). mp.: 194–197 °C. 1H-NMR (DMSO-d6, 600 MHZ): δ 9.48 (s, 1H, NH, exchangeable with D2O), 8.55 (d, 1H, J = 10.0 Hz, NH, exchangeable with D2O), 8.17 (d, 1H, J = 0.5 Hz, triazole H), 7.90 (s, 1H, aminobenzene H), 7.77 (s, 1H, triazole H), 7.54 (d, 1H, J = 19.9 Hz, aminobenzene H), 7.47 (d, 1H, J = 14.9 Hz, aminobenzene H), 7.41 (dd, 1H, J = 2.5 Hz, 14.7 Hz, phenyl H), 7.33 (t, 1H, J = 14.9 Hz, aminobenzene H), 7.05–7.15 (m, 2H, phenyl H), 5.10–5.14 (m, 1H, oxazolidinone H), 4.94–4.08 (m, 1H, d-alanine CH), 4.83 (d, 2H, J = 5.10, CH2), 4.21 (t, 1H, J = 9.0 Hz, oxazolidinone H), 3.86 (dd, 1H, J = 5.5 Hz, 9.1 Hz, oxazolidinone H), 3.58–3.70 (m, 4H, piperazine H), 2.92–3.05 (m, 4H, piperazine H), 1.48 (s, 9H, (CH3)3), 1.31(d, 3H, J = 7.0 Hz, CH3). IR (KBr pellet, cm−1): ν 3409, 3255, 2979, 2934, 1763, 1639, 1517, 1480, 1443, 1322, 1233, 1159, 1028. HRMS (m/z): for C31H37FN8O6: 636.2820, found 637.2976 (M+ + H).
The intermediate compound 17b was deprotected via a similar procedure to 16a to give the title Compound 9k as a solid, 180 mg, yield 75%, mp.: 129–132 °C. 1H-NMR (DMSO-d6, 600 MHZ): δ 8.54 (d, 1H, J = 7.4 Hz, NH, exchangeable with D2O), 8.18 (s,1H, triazole H), 7.78 (d, 1H, J = 0.5 Hz, triazole H), 7.35–7.45 (m, 3H, phenyl H), 7.28 (t, 1H, J = 7.8 Hz, phenyl H), 7.12–7.46 (m, 1H, phenyl H), 7.07 (t, 1H, J = 9.3 Hz, phenyl H), 7.01 (d, 1H, J = 7.5 Hz, phenyl H), 5.11–5.15 (m, 1H, oxazolidinone H), 4.94–4.99 (m, 1H, d-alanine CH), 4.84 (d, 2H, J = 5.0 Hz, CH2), 4.20–4.23 (m, 2H, oxazolidinone H), 3.87 (dd, 1H, J = 5.7 Hz, 9.3 Hz, oxazolidinone H, overlapping with +NH3 signal), 3.50–3.88 (br. m, 7H, piperazine H, overlapping with +NH3 signal, which is exchangeable with D2O), 2.95–3.27 (br. d, 4H, piperazine H), 1.31 (d, 3H, J = 7.0 Hz, CH3). 13C-NMR (DMSO-d6, 600 MHZ): δ 170.4, 165.7, 158.3, 158.0, 155.4, 153.7, 153.5, 135.4, 135.1, 133.4, 133.3, 133.2, 129.1, 125.9, 125.9, 119.9, 119.8, 117.1, 116.4, 115.1, 114.3, 106.9, 106.7, 70.8, 51.7, 50.6, 50.3, 47.3, 47.1, 45.1, 44.9, 43.0, 41.6, 17.5. IR (KBr pellet, cm−1): ν 3423, 2921, 1753, 1674, 1638, 1518, 1447, 1326, 1231, 1201, 1135, 1028. HRMS (m/z): for C28H30F4N8O6: 650.2224, found 650.0204 (M+).

2.2.23. Preparation of N-(R)-1-(4-(4-((R)-5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperazin-1-yl)-1-oxopropan-2-yl)-4-aminobenzamide 2,2,2-trifluoroacetate 9l

Compound 9l was prepared via a similar procedure to 9j from 3-((tert-butoxycarbonyl) amino benzoic acid and 16a (1.00 g, 1.881 mmol) to give the intermediate compound 17c as a white solid, 352 mg, yield 32%, recrystallized (EtOAc), mp.: 142–145 °C. 1H-NMR (DMSO-d6, 600 MHZ): δ 9.62 (s, 1H, NH, exchangeable with D2O), 8.47 (d, 1H, J = 7.6 Hz, NH, exchangeable with D2O), 8.17 (d, 1H, J = 0.9 Hz, triazole H), 7.82 (d, 2H, J = 8.8 Hz, aminobenzene H), 7.77 (d, 1H, J = 0.7 Hz, triazole H), 7.52 (d, 2H, J = 8.8 Hz, aminobenzene H), 7.43 (dd, 1H, J = 2.5 Hz, 14.7 Hz, phenyl H), 7.13 (dd, 1H, J = 2.3 Hz, 8.8 Hz, phenyl H), 7.06 (t, 1H, J = 8.8 Hz, phenyl H), 5.11–5.14 (m, 1H, oxazolidinone H), 4.95–5.00 (m, 1H, d-alanine CH), 4.83 (d, 2H, J = 5.1 Hz, CH2), 4.21 (t, 1H, J = 9.2 Hz, oxazolidinone H), 3.86 (dd, 1H, J = 5.7 Hz, 9.3 Hz, oxazolidinone H), 3.61–3.70 (m, 4H, piperazine H), 2.95–2.98 (m, 4H, piperazine H), 1.49 (s, 9H, (CH3)3), 1.31 (d, 3H, J = 7.0 Hz, CH3). IR (KBr pellet, cm−1): ν 3409, 2979, 2932, 1758, 1730, 1637, 1517, 1446, 1320, 1232, 1159, 1027. HRMS (m/z): for C31H37FN8O6: 636.2820, found 637.3028 (M+ + H).
The intermediate compound 17c was deprotected via a similar procedure to 16a to give the title Compound 9l as a solid, 261 mg, yield 71%, recrystallized (EtOAc); mp.: 139–142 °C. 1H-NMR (DMSO-d6, 600 MHZ): δ 8.20 (d, 1H, J = 7.6 Hz, NH, exchangeable with D2O), 8.18 (d,1H, J = 0.5 Hz, triazole H), 7.78 (s, 1H, triazole H), 7.67 (d, 1H, J = 8.6 Hz, aminobenzene H), 7.43 (dd, 1H, J = 2.4 Hz, 14.6 Hz, phenyl H), 7.14 (dd, 1H, J = 2.6 Hz, 8.9 Hz, phenyl H), 7.06 (t, 1H, J = 9.3 Hz, phenyl H), 6.63 (d, 2H, J = 8.5 Hz, phenyl H), 5.11–5.16 (m, 1H, oxazolidinone H), 4.92–4.98 (m, 1H, d-alanine CH), 4.83 (d, 2H, J = 5.0 Hz, CH2), 4.21 (t, 2H, oxazolidinone H overlaps with +NH3 signal), 3.90–4.50 (br. m, 4H, oxazolidinone H overlaps with +NH3 signal), 3.68 (dd, 1H, J = Hz, oxazolidinone H), 3.60–3.69 (m, 4H, piperazine H), 2.94–3.30 (br. d, 4H, piperazine H), 1.29 (d, 3H, J = 6.9 Hz, CH3). 13C-NMR (DMSO-d6, 600 MHZ): δ 170.8, 165.5, 158.3, 158.1, 155.4, 153.7, 153.5, 135.4, 135.4, 133.8, 133.7, 133.4, 133.3, 133.2, 129.2, 129.0, 128.3, 125.9, 125.9, 119.9, 119.7, 114.8, 114.3, 106.8, 106.7, 70.8, 51.7, 51.7, 50.6, 50.3, 47.3, 47.1, 47.1, 44.9, 44.7, 43.0, 41.6, 17.6. IR (KBr pellet, cm−1): ν 3364, 2985, 2835, 1750, 1674, 1635, 1518, 1448, 1231, 1199, 1134, 1027. HRMS (m/z): for C28H30F4N8O6: 650.2224, found 650.0215 (M+).

2.2.24. Preparation of N-((S)-1-(4-(4-((R)-5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperazin-1-yl)-1-oxopropan-2-yl)-2-aminobenzamide 2,2,2-trifluoroacetate 10j

Compound 10j was prepared via a similar procedure to 9j starting from 3-((tert-butoxycarbonyl) amino benzoic acid and 16b (1.00 g, 1.881 mmol) to give the intermediate compound 18a as a white solid, 377 mg, yield 32%, recrystallized (EtOAc), mp.: 129–131 °C. 1H-NMR (DMSO-d6, 600 MHZ): δ 10.46 (s, 1H, NH, exchangeable with D2O), 8.91 (d, 1H, J = 7.3 Hz, NH, exchangeable with D2O), 8.20 (d, 1H, J = 8.5 Hz, phenyl H), 8.18 (d, 1H, J = 0.5 Hz, triazole H), 7.81 (d,1H, J = 7.9 Hz, phenyl H), 7.78 (s, 1H, triazole H), 7.47–7.50 (m, 1H, phenyl H), 7.43 (dd, 1H, J = 2.4 Hz, 14.7 Hz, phenyl H), 7.08–7.14 (m, 3H, phenyl H), 5.12–5.14 (m, 1H, oxazolidinone H), 4.95–5.00 (m, 1H, l-alanine CH), 4.84 (d, 2H, J = 5.0 Hz, CH2), 4.21 (t, 1H, J = 9.2 Hz, oxazolidinone H), 3.87 (dd, 1H, J = 5.7 Hz, 9.3 Hz, oxazolidinone H), 3.60–3.78 (m, 4H, piperazine H), 2.90–3.06 (m, 4H, piperazine H), 1.45 (s, 9H, (CH3)3), 1.34 (d, 3H, J = 7.0 Hz, CH3). 13C-NMR (DMSO-d6, 600 MHZ): δ 170.2, 167.8, 155.4, 153.8, 153.5, 152.1, 139.4, 135.4, 135.4, 133.4, 133.3, 133.3, 132.2, 128.6, 125.9, 121.4, 119.8, 119.3, 118.5, 114.3, 106.8, 106.7, 79.8, 70.8, 64.9, 51.7, 50.7, 50.2, 47.1, 45.3, 44.9, 41.7, 30.7, 27.9, 17.1. IR (KBr pellet, cm−1): ν 3350, 3114, 2978, 2931, 1757, 1718, 1647, 1589, 1442, 1227, 1160, 1110, 1050, 1026. HRMS (m/z): for C31H37FN8O6: 636.2820, found 637.0000 (M+ + H). LRMS (m/z): 536.3 (M+ − (CH3)2C=CH2 + CO2). Anal. calcd. for CHN: C: 58.48, H: 5.86, N: 17.6, found C: 58.50, H: 6.38, N: 18.04.
The intermediate compound 18a was deprotected via a similar procedure to 16b to give 10j as a white solid, 240 mg, yield 57%; recrystallized (EtOAc), mp.: 168–173 °C. 1H-NMR (DMSO-d6, 600 MHZ): δ 8.40 (d, 1H, J = 7.4 Hz, NH, exchangeable with D2O), 8.18 (d, 1H, J = 0.9 Hz, triazole H), 7.78 (d, 1H, J = 0.7 Hz, triazole H), 7.60 (dd, 1H, J = 1.3 Hz, 7.9 Hz, phenyl H), 7.43 (dd, 1H, J = 2.5 Hz, 14.7 Hz, phenyl H), 7.17–7.20 (m, 1H, phenyl H), 7.14 (dd, 1H, J = 2.3 Hz, 8.8 Hz, phenyl H), 7.07 (t, 1H, J = 9.3 Hz, phenyl H), 6.75 (d, 1H, J = 7.9 Hz, phenyl H), 6.60 (t, 1H, J = 7.5 Hz, phenyl H), 5.10–5.15 (m, 1H, oxazolidinone H), 4.92–4.96 (m, 1H, l-alanine CH), 4.83 (d, 2H, J = 5.1 Hz, CH2), 4.21 (t, 1H, J = 9.2 Hz, oxazolidinone H), 3.87 (dd, 1H, J = 5.7 Hz, 9.3 Hz, oxazolidinone H), 3.40–3.80 (br. m, 7H, piperazine H, overlapping with +NH3 signal, which is exchangeable with D2O), 2.95–3.01 (br. d, 4H, piperazine H), 1.31 (s, 3H, J = 7.0 Hz, CH3). 13C-NMR (DMSO-d6, 600 MHZ): δ 170.6, 168.0, 158.3, 158.0, 155.4, 153.7, 153.5, 135.4, 135.4, 133.4, 133.3, 133.2, 131.9, 128.5, 125.9, 119.7, 116.8, 115.5, 115.2, 114.3, 106.8, 106.7, 70.8, 51.7, 50.7, 50.3, 47.1, 44.9, 44.7, 41.6, 30.7, 17.4. IR (KBr pellet, cm−1): ν 3427, 2984, 2922, 1755, 1635, 1587, 1517, 1447, 1327, 1230, 1200, 1138, 1028. HRMS (m/z): for C28H30F4N8O6: 650.2224, found 650.0234 (M+).

2.2.25. Preparation of N-((S)-1-(4-(4-((R)-5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperazin-1-yl)-1-oxopropan-2-yl)-3-aminobenzamide 2,2,2-trifluoroacetate 10k

Compound 10k was prepared via a similar procedure to 9j starting from 3-((tert-butoxycarbonyl) amino benzoic acid and 16b (1.00 g, 1.881 mmol) to give the intermediate compound 18b as a white solid, 480 mg, yield 43%, recrystallized (EtOAc); mp.: 171–174 °C. 1H-NMR (DMSO-d6, 600 MHZ): δ 9.50 (s, 1H, NH, exchangeable with D2O), 8.57 (d, 1H, J = 7.6 Hz, NH, exchangeable with D2O), 8.18 (d, 1H, J = 0.9 Hz, triazole H), 7.98 (s, 1H, phenyl H), 7.78 (d,1H, J = 0.9 Hz, triazole H), 7.55 (d, 1H, J = 7.9 Hz, phenyl H), 7.48 (d, 1H, J = 7.9 Hz, phenyl H), 7.44 (dd, 1H, J = 2.5 Hz, 14.7 Hz, phenyl H), 7.34 (t, 1H, J = 9.2 Hz, phenyl H), 7.13 (dd, 1H, J = 2.3 Hz, 9.3 Hz, phenyl H), 7.07 (t, 1H, J = 9.3 Hz, phenyl H), 5.12–5.13 (m, 1H, oxazolidinone H), 4.95–4.97 (m, 1H, l-alanine CH), 4.84 (d, 2H, J = 5.1 Hz, CH2), 4.21 (t, 1H, J = 9.2 Hz, oxazolidinone H), 3.87 (dd, 1H, J = 5.7 Hz, 9.3 Hz, oxazolidinone H), 3.61–3.70 (br. m, 4H, piperazine H), 2.96–3.00 (br. d, 4H, piperazine H), 1.49 (s, 9H, (CH3)3), 1.32 (d, 3H, J = 7.0 Hz, CH3). 13C-NMR (DMSO-d6, 600 MHZ): δ 170.4, 165.9, 155.4, 153.7, 153.5, 152.8, 139.6, 135.4, 135.4, 134.8, 133.4, 133.3, 133.2, 128.4, 125.8, 120.9, 120.8, 119.8, 119.7, 117.5, 114.3, 106.8, 106.6, 79.2, 70.8, 51.7, 50.6, 50.3, 47.1, 45.1, 44.9, 41.6, 28.1, 17.4. IR (KBr pellet, cm−1): ν 3414, 3256, 2978, 1760, 1730, 1637, 1556, 1519, 1441, 1414, 1237, 1158, 1029. HRMS (m/z): for C31H37FN8O6: 636.2820, found 637.0000 (M+ + H). CHN Anal. calcd.: C: 58.48, H: 5.86, N: 17.60, found C: 58.78, H: 6.29, N: 17.60.
The intermediate compound 18b was deprotected via a similar procedure to 16b to give 10k as a white solid, 323 mg, yield 71%; recrystallized (EtOAc), mp.: 203–208 °C. 1H-NMR (DMSO-d6, 600 MHZ): δ 8.80 (d, 1H, J = 7.4 Hz, NH, exchangeable with D2O), 8.17 (d, 1H, J = 0.6 Hz, triazole H), 7.87 (d, 1H, J = 7.8 Hz, phenyl H), 7.77 (d, 1H, J = 6.1 Hz, triazole H and phenyl H), 7.56 (t, 1H, J = 7.9 Hz, phenyl H), 7.47 (d, 1H, J = 8.0 Hz, phenyl H), 7.43 (dd, 1H, J = 2.4 Hz, 14.7 Hz, phenyl H), 7.13 (dd, 1H, J = 2.2 Hz, 8.9 Hz, phenyl H), 7.06 (t, 1H, J = 9.3 Hz, phenyl H), 5.10–5.14 (m, 1H, oxazolidinone H), 4.96–5.00 (m, 1H, l-alanine CH), 4.82 (d, 2H, J = 5.0 Hz, CH2), 4.20 (t, 1H, J = 9.2 Hz, oxazolidinone H), 3.86 (dd, 1H, J = 5.7 Hz, 9.3 Hz, oxazolidinone H, overlapping with +NH3 signal), 3.50–3.86 (br. m, 7H, piperazine H, overlapping with +NH3 signal, exchangeable with D2O), 2.95–3.00 (m, 4H, piperazine H), 1.32 (d, 3H, J = 6.9 Hz, CH3). 13C-NMR (DMSO-d6, 600 MHZ): δ 170.4, 165.7, 158.3, 158.0, 155.4, 153.7, 153.5, 135.4, 135.1, 133.4, 133.3, 133.2, 129.1, 125.9, 125.9, 119.9, 119.8, 117.1, 116.4, 115.1, 114.3, 106.9, 106.7, 70.9, 51.7, 50.6, 50.3, 47.3, 47.1, 45.1, 44.9, 43.0, 41.6, 17.5. IR (KBR pellet, cm−1): 3406, 3061, 2921, 2854, 2585, 1758, 1641, 1519, 1482, 1443, 1417, 1336, 1280, 1216, 1167, 1147, 1023. HRMS (m/z): for C28H30F4N8O6: 650.2224, found 650.0000 (M+).

2.2.26. Preparation of N-((S)-1-(4-(4-((R)-5-((1H-1,2,3-triazol-1-yl)methyl)-2-oxooxazolidin-3-yl)-2-fluorophenyl)piperazin-1-yl)-1-oxopropan-2-yl)-4-aminobenzamide 2,2,2-trifluoroacetate 10l

Compound 10l was prepared via a similar procedure to 9j starting from 3-((tert-butoxycarbonyl) amino benzoic acid and 16b (1.00 g, 1.881 mmol) to give the intermediate compound 18c as a white solid, 485 mg, yield 43%, recrystallized (EtOAc); mp.: 139–142 °C. 1H-NMR (DMSO-d6, 600 MHZ): δ 9.64 (s, 1H, NH, exchangeable with D2O), 8.49 (d, 1H, J = 7.6 Hz, NH, exchangeable with D2O), 8.18 (d, 1H, J = 0.9 Hz, triazole H), 7.83 (d, 2H, J = 8.8 Hz, phenyl H), 7.78 (d, 1H, J = 0.8 Hz, triazole H), 7.52 (d, 2H, J = 8.7 Hz, phenyl H), 7.43 (dd, 1H, J = 2.5 Hz, 14.7 Hz, phenyl H), 7.13 (dd, 1H, J = 2.3 Hz, 8.8 Hz, phenyl H), 7.05 (t, 1H, J = 9.3 Hz, phenyl H), 5.11–5.15 (m, 1H, oxazolidinone H), 4.95–5.00 (m, 1H, d-alanine CH), 4.84 (d, 2H, J = 5.1 Hz, CH2), 4.21 (t, 1H, J = 9.2 Hz, oxazolidinone H), 3.87 (dd, 1H, J = 5.7 Hz, 9.3 Hz, oxazolidinone H), 3.61–3.70 (br. m, 4H, piperazine H), 2.95-2.98 (br. m, 4H, piperazine H), 1.49 (s, 9H, (CH3)3), 1.31 (d, 3H, J = 7.0 Hz, CH3). 13C-NMR (DMSO-d6, 600 MHZ): δ 170.6, 165.2, 155.3, 153.7, 153.5, 152.9, 142.4, 135.4, 135.4, 133.4, 133.3, 133.2, 128.3, 127.2, 125.8, 119.8, 119.7, 117.0, 114.3, 114.3, 106.8, 106.7, 79.5, 70.8, 64.9, 51.7, 50.6, 50.3, 47.1, 44.9, 41.6, 28.1, 17.5. IR (KBr pellet, cm−1): ν 3409, 2979, 2932, 1757, 1727, 1637, 1446, 1320, 1232, 1159, 1027. HRMS (m/z): for C31H37FN8O6: 636.2820, found 637.0000 (M+ + H).
The intermediate compound 18c was deprotected via a similar procedure to 16a to give 10l as a white solid, 229 mg, yield 63%; recrystallized (EtOAc), mp.: 239–242 °C. 1H-NMR (DMSO-d6, 600 MHZ): δ 8.60 (br. d, 1H, J = 6.5 Hz, NH, exchangeable with D2O), 8.17 (d, 1H, J = 0.8 Hz, triazole H), 7.89 (d, 2H, J = 8.5 Hz, phenyl H), 7.76 (s, 1H, J = 0.7 Hz, triazole H), 7.42 (dd, 1H, J = 2.5 Hz, 14.7 Hz, phenyl H), 7.21 (d, 2H, J = 8.0 Hz, phenyl H), 7.12 (dd, 1H, J = 2.3 Hz, 8.8 Hz, phenyl H), 7.06 (t, 1H, J = 9.3 Hz, phenyl H), 5.10–5.13 (m, 1H, oxazolidinone H), 4.94–4.99 (m, 1H, l-alanine CH), 4.82 (d, 2H, J = 5.1 Hz, CH2), 4.20 (t, 1H, J = 9.2 Hz, oxazolidinone H, partially overlaps with the +NH3 signal), 3.74–4.30 (br., 3H, +NH3, exchangeable with D2O, partially overlaps with oxazolidinone H) 3.86 (dd, 1H, J = 5.7 Hz, 9.3 Hz, oxazolidinone H, partially overlaps with the +NH3 signal), 3.59–3.72 (br. m, 4H, piperazine H), 2.95-2.99 (br. d, 4H, piperazine H), 1.31 (s, 3H, J = 7.0 Hz, CH3). 13C-NMR (DMSO-d6, 600 MHZ): δ 170.5, 165.0, 155.3, 153.7, 153.4, 135.3, 135.3, 133.3, 133.2, 129.1, 128.9, 125.8, 119.7, 119.4, 114.3, 106.9, 106.7, 70.7, 51.7, 50.6, 50.2, 47.1, 47.1, 45.0, 44.9, 41.9, 17.4. IR (KBr pellet, cm−1): ν 3407, 2833, 2575, 1758, 1640, 1515, 1417, 1234, 1217, 1020. HRMS (m/z): for C28H30F4N8O6: 650.2224, found 649.0000 (M+ − H) and 537.000 (M+ − CF3CO2H).

2.3. Antibacterial Susceptibility Testing

Antibacterial susceptibility testing was performed by determining the minimum inhibitory concentrations (MIC, µg/mL), which is defined as the lowest concentration of a compound that inhibits visible bacterial growth. The MIC was determined on Mueller–Hinton (MH) agar with medium containing dilutions of antibacterial agents ranging from 0.12–32 μg/mL. Linezolid [24,28], used as the reference standard antibacterial agent, was dissolved in 60% ethanol in water and test compounds in 80% DMSO in water. The antibacterial activity of the compounds was evaluated against 6 standard reference Gram-positive and Gram-negative bacterial strains available at the MRSA Reference Laboratory, Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait. The Gram-positive standard bacterial strains used in this study consisted of S. aureus ATCC 25923, S. epidermidis ATCC 12228 and E. faecalis ATCC 29212, and the Gram-negative bacterial strains included E. coli ATCC 25922, H. influenzae ATCC 49247 and M. catarrhalis ATCC 8176. MH agar plates were used for all staphylococci and enterococci, while the MH agar plates were supplemented with 5% sheep blood to facilitate the growth of S. pneumoniae, H. influenzae and M. catarrhalis. For all, the final bacterial concentration for inocula was 107 CFU/mL, incubated at 35 °C for 18 h.

3. Results and Discussion

3.1. Chemistry

The final compounds, (d)-alaninyl isomers 9a–l and the (l)-alaninyl isomers 10a–l, were synthesized as outlined in Scheme 1 according to reported literature procedures starting from commercially available piperazine 11 and 3,4-difluoronitrobenzene 12 [18,23,28] with minor modifications to the synthetic route and outlined in Scheme 1. Using standard organic transformation, intermediate compound 5-triazolylmethyl derivative 13 was deprotected using TFA (trifluoroacetic acid) in DCM (dichloromethane) to afford the TFA salt 14 in quantitative yield. Compound 14 was coupled with tert-(d)- and tert-(l)-alanine using dicyclohexylcarbodiimide and 1-hydroxybenzotriaole as coupling reagents under standard derivatization protocols to give the tert-(d)-alaninyl 15a and the tert-(l)-alaninyl derivatives 15b, respectively in very good yields. Deprotection of Compounds 15a and 15b, in TFA and DCM, gave the (d)-alaninyl 16a and the (l)-alaninyl 16b TFA salts in excellent yields. Further chemical transformation via the reaction of the TFA salts with activated nitro-benzoic and nitro-heteroaroyl acids or the respective acid chlorides and nitrobenzene sulfonyl chlorides yielded the (d)-alaninyl 9a–f and (l)-alaninyl 10a–f amide and the (d)-alaninyl 9g–i and (l)-alaninyl 10g–i sulfonamide derivatives, respectively. For preparation of the amino benzoyl derivatives 9j–l and 10j–l, the TFA salts 16a–b were reacted with 2-, 3- and 4-((tert-butoxycarbonyl) amino benzoic acids to afford the boc-protected (d)-alaninyl 17a–c and (l)-alaninyl 18a–c amide derivatives, respectively. The deprotection of Boc from these derivatives using TFA in DCM gave the final 2-, 3- and 4-aminobenzamide (d)-alaninyl 9j–l and (l)-alaninyl 10j–l derivatives as TFA salts. All compounds were isolated, purified and characterized as reported in the experimental sections and evaluated for their antibacterial activities as detailed in the Antibacterial Evaluation Section.

3.2. Antibacterial Evaluation

A total of twenty-four final compounds comprised of the (d)-alaninyl 9a–l and (l)-alaninyl 10a–l oxazolidinone derivatives containing nitro- and amino-aroyl substitutions and two tert-butoxycarbonyl intermediate compounds (15a and 15b) were evaluated for their antibacterial activity against standard Gram-positive and Gram-negative bacterial strains. The Gram-positive standard bacterial strains used in this study consisted of S. aureus ATCC 25923, S. epidermidis ATCC 12228 and E. faecalis ATCC 29212, while the Gram-negative bacterial strains included Escherichia coli ATCC 25922, Haemophilus influenzae ATCC 49247 and Moraxella catarrhalis ATCC 8176. Antibacterial susceptibility testing was carried out using the agar dilution method on Mueller–Hinton (MH) agar according to the Clinical and Laboratory Standard Institute (CSLI) [29], and the data are presented in Table 1. With a minimum inhibitory concentration of >32 µg/mL, none of the compounds demonstrated acceptable antibacterial activity against the Gram-negative bacterial strains, namely E. coli ATCC 25922 and H. influenzae ATCC 49247. Overall, the novel (d)-alaninyl and (l)-alaninyl oxazolidinones showed moderate to strong antibacterial activity against the Gram-positive bacterial strains tested with a MIC range of 2–>16 µg/mL. In general, there is no identifiable significant difference between the antibacterial activity of the (d)-alaninyl and (l)-alaninyl oxazolidinone derivatives, suggesting similar binding interaction at the ribosomal receptor binding site irrespective of the stereochemistry at the alaninyl side-chain spacer. However, in some of the derivatives, the (l)-alaninyl spacer seemed to have a slightly improved antibacterial activity; for example, the 4-nitrobenzoyl (d)-alaninyl oxazolidinone derivative 9c (MIC: 8 and 4 µg/mL) was 1–3-fold less active than the corresponding (l)-alaninyl derivative 10c (MIC: 2 and 2 µg/mL) against S. epidermidis ATCC 12228 and E. faecalis ATCC 29212, respectively. Similarly, the 5-nitrofuran-2-carbonyl substituted (l)-alaninyl oxazolidinone derivative 10e (MIC: 2 and 2 µg/mL) demonstrated 1–3-fold superior antibacterial activity to the corresponding (d)-alaninyl oxazolidinone derivative 9e (MIC: 8 and 4 µg/mL), against S. aureus ATCC 25923 and E. faecalis ATCC 29212, respectively. Overall, aminoaryl, nitroaroyl and nitroheteroaroyl substitutions in the (d/l)-alaninyl oxazolidinone derivatives favored retention of antibacterial activity and showed selective activity against S. epidermidis ATCC 12228 and E. faecalis ATCC 29212. The precise reasons for this are unknown. However, the presence of these moieties might result in additional interactions at the ribosomal receptor binding sites, due to a combination of H-bond acceptor and/or donor groups coupled with potential van der Waals interactions [15,27]. In addition, the observed selective activity against S. epidermidis ATCC 12228 and E. faecalis ATCC 29212 could also suggest a subtle difference in the conformation of rRNA nucleotides in these two bacterial strains, which may have some effect on the interaction with the compounds. Conformation changes of rRNA nucleotide had been utilized to explain dramatic differences in the interactions for some antibiotics, namely macrolides and lincosamides, respectively [14,30]. The nitro-substituted derivatives showed improved activity against the Gram-negative respiratory pathogen M. catarrhalis ATCC 25922 with an MIC range of 2–8 µg/mL. In addition, previous studies from our laboratory and others have shown that incorporation of 5-nitro-2-furoyl and 3,5-dinitrobenzoyl moieties selectively enhanced antibacterial activity of N-substituted-piperazinyl oxazolidinone derivatives [27,31]. However, we anticipated that the incorporation of the alanine spacer group may result in potential hydrogen bond acceptor and donor interactions in addition to hydrophobic interaction due to the presence of the aroyl, heteroaroyl and methyl moieties, whose orientation at the ribosomal receptor binding site may result in favorable stereochemistry that might positively influence the observed antibacterial activity. Moreover, the 5-nitrofuran-2-carbonyl (d/l)-alaninyl oxazolidinone derivatives were less active than the previously reported 5-nitrofuran-2-carbonyl glycinyl oxazolidinone derivatives with demonstrated potent antibacterial activity, with MIC value ranges of 2–8 and 0.06–0.50 µg/mL [23], respectively. The findings from the present study further suggest that the glycinyl spacer probably favors or permits a more effective interaction of the compounds at the bacterial ribosomal receptor binding site [27], which eventually translates into more potent antibacterial activity [23]. Furthermore, previous studies from our laboratory and others have demonstrated that unsubstituted-benzenesulfonyl and tolylsulfonyl groups generally resulted in oxazolidinone derivatives with reduced antibacterial activity compared with the benzoyl and substituted-benzoyl derivatives [26,27,31]. Therefore, data from the present study further elaborate that the introduction of the electron withdrawing nitro group alone does not significantly improve antibacterial activity. This is evident from the fact that the nitrobenzenesulfonyl (d/l)-alaninyl oxazolidinone derivatives were also generally less active than the corresponding nitrobenzoyl derivatives with an MIC value range of 2–>16 µg/mL.

4. Conclusions

In conclusion, all the newly synthesized d- and l-alaninyl oxazolidinone derivatives demonstrated antibacterial activity against all standard Gram-positive bacterial strains and one Gram-negative bacterial strain tested. The compounds were devoid of activity against standard Gram-negative bacterial strains, namely E. coli and H. influenzae. Moreover, the 3,5-dinitrobenzoyl and 5-nitroheteroaroyl substitution pattern on alanine nitrogen enhanced antibacterial activity, while amino-aroyl substitution seems to selectively favor activity against S. epidermidis and E. faecalis. The introduction of nitro groups on the benzenesulfonyl derivatives did not improve their antibacterial potency. Finally, the incorporation of the d- and l-alaninyl spacer did not have a significant effect on the activity of this series of compounds.

Author Contributions

Conceptualization, O.A.P. and E.E.U.; Methodology, O.A.P. and E.E.U.; Performed, R.J.D.; Formal Analysis, O.A.P. and E.E.U.; Investigation, O.A.P., E.E.U. and R.J.D.; Data Curation, R.J.D.; Writing-Original Draft Preparation, O.A.P. and E.E.U.; Writing-Review & Editing, O.A.P., E.E.U. and R.J.D.; Supervision, O.A.P. and E.E.U.; Project Administration, O.A.P.; Funding Acquisition, O.A.P. and E.E.U.

Acknowledgments

This research was funded by the Research Sector, Kuwait University Research Project Grant No. PC01/09 (OAP), and the General Facilities Science (GF-S), Faculty of Science, Instrument Grant Nos. GS01/01 (Bruker DPX 400 MHz NMR), GS01/03 (GC MS DFS—Thermo and Bruker 600 MHz NMR), GS01/05 (Jasco FT/IR-6300 and CHNS—Vario Micro Cube) and GS02/10 (LC MS/MS—Waters QToF). The authors would like to thank Vidhya Thomas for technical support.

Conflicts of Interest

The authors declare no conflict of or secondary interest.

References

  1. Butler, M.S.; Blaskovich, M.A.; Cooper, M.A. Antibiotics in the clinical pipeline at the end of 2015. J. Antibiot. 2017, 70, 3–24. [Google Scholar] [CrossRef] [PubMed]
  2. Fernandes, P.; Martens, E. Antibiotics in late clinical development. Biochem. Pharmacol. 2017, 133, 152–163. [Google Scholar] [CrossRef] [PubMed]
  3. Torrice, M. Antibaterial boom and bust. C&EN 2013, 91, 34–37. [Google Scholar]
  4. Frieden, T. Antibiotic Resistance Threats in the United States; U.S. Centers for Disease Control and Prevention: Atlanta, GA, USA, 2013; pp. 1–114.
  5. Holmes, N.E.; Tong, S.Y.; Davis, J.S.; van Hal, S.J. Treatment of methicillin-resistant Staphylococcus aureus: Vancomycin and beyond. Semin. Respir. Crit. Care Med. 2015, 36, 17–30. [Google Scholar] [CrossRef] [PubMed]
  6. Poce, G.; Cocozza, M.; Consalvi, S.; Biava, M. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development. Eur. J. Med. Chem. 2014, 86, 335–351. [Google Scholar] [CrossRef] [PubMed]
  7. WHO. Global Tuberculosis Report 2016. Available online: http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng.pdf?ua=1 (accessed on 22 April 2018).
  8. Bassetti, M.; Righi, E. Development of novel antibacterial drugs to combat multiple resistant organisms. Langenbeck’s Arch. Surg. 2015, 400, 153–165. [Google Scholar] [CrossRef] [PubMed]
  9. Holmes, N.E.; Howden, B.P. What’s new in the treatment of serious MRSA infection? Curr. Opin. Infect. Dis. 2014, 27, 471–478. [Google Scholar] [CrossRef] [PubMed]
  10. Xu, H.B.; Jiang, R.H.; Li, L.; Xiao, H.P. Linezolid in the treatment of MDR-TB: A retrospective clinical study. Int. J. Tuberc. Lung D 2012, 16, 358–363. [Google Scholar] [CrossRef] [PubMed]
  11. Ager, S.; Gould, K. Clinical update on linezolid in the treatment of Gram-positive bacterial infections. Infect. Drug Resist. 2012, 5, 87–102. [Google Scholar] [CrossRef] [PubMed]
  12. Shaw, K.J.; Barbachyn, M.R. The oxazolidinones: Past, present, and future. Ann. N. Y. Acad. Sci. 2011, 1241, 48–70. [Google Scholar] [CrossRef] [PubMed]
  13. Shinabarger, D.L.; Marotti, K.R.; Murray, R.W.; Lin, A.H.; Melchior, E.P.; Swaney, S.M.; Dunyak, D.S.; Demyan, W.F.; Buysse, J.M. Mechanism of action of oxazolidinones: Effects of linezolid and eperezolid on translation reactions. Antimicrob. Agents chemother. 1997, 41, 2132–2136. [Google Scholar] [PubMed]
  14. Wilson, D.N.; Nierhaus, K.H. The oxazolidinone class of drugs find their orientation on the ribosome. Mol. Cell 2007, 26, 460–462. [Google Scholar] [CrossRef] [PubMed]
  15. Ippolito, J.A.; Kanyo, Z.F.; Wang, D.; Franceschi, F.J.; Moore, P.B.; Steitz, T.A.; Duffy, E.M. Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J. Med. Chem. 2008, 51, 3353–3356. [Google Scholar] [CrossRef] [PubMed]
  16. Lawrence, K.R.; Adra, M.; Gillman, P.K. Serotonin toxicity associated with the use of linezolid: A review of postmarketing data. Clin. Infect. Dis. 2006, 42, 1578–1583. [Google Scholar] [CrossRef] [PubMed]
  17. Leach, K.L.; Brickner, S.J.; Noe, M.C.; Miller, P.F. Linezolid, the first oxazolidinone antibacterial agent. Ann. N. Y. Acad. Sci. 2011, 1222, 49–54. [Google Scholar] [CrossRef] [PubMed]
  18. Reck, F.; Zhou, F.; Girardot, M.; Kern, G.; Eyermann, C.J.; Hales, N.J.; Ramsay, R.R.; Gravestock, M.B. Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A. J. Med. Chem. 2005, 48, 499–506. [Google Scholar] [CrossRef] [PubMed]
  19. Srivastava, B.K.; Soni, R.; Patel, J.Z.; Jain, M.R.; Patel, P.R. Oxazolidinone antibacterials and our experience. Anti-Infect. Agents Med. Chem. 2008, 7, 258–280. [Google Scholar] [CrossRef]
  20. Poel, T.J.; Thomas, R.C.; Adams, W.J.; Aristoff, P.A.; Barbachyn, M.R.; Boyer, F.E.; Brieland, J.; Brideau, R.; Brodfuehrer, J.; Brown, A.P.; et al. Antibacterial oxazolidinones possessing a novel C-5 side chain(5R)-trans-3-[3-fluoro-4-(1-oxotetrahydrothiopyran-4-yl-phenyl]-2-oxooxazolidinone-5-carboxylic acid amide (PF-00422602), a new lead compound. J. Med. Chem. 2007, 50, 5886–5889. [Google Scholar] [CrossRef] [PubMed]
  21. Al-Tannak, N.F.; Phillips, O.A. Antimycobacterial Activities of N-Substituted-Glycinyl 1H-1,2,3-Triazolyl Oxazolidinones and Analytical Method Development and Validation for a Representative Compound. Sci. Pharm. 2017, 85, 34. [Google Scholar] [CrossRef] [PubMed]
  22. Hauck, S.I.; Cederberg, C.; Doucette, A.; Grosser, L.; Hales, N.J.; Poon, G.; Gravestock, M.B. New carbon-linked azole oxazolidinones with improved potency and pharmacokinetics. Bioorg. Med. Chem. Lett. 2007, 17, 337–340. [Google Scholar] [CrossRef] [PubMed]
  23. Phillips, O.A.; Udo, E.E.; Abdel-Hamid, M.E.; Varghese, R. Synthesis and antibacterial activities of N-substituted-glycinyl 1H-1,2,3-triazolyl oxazolidinones. Eur. J. Med. Chem. 2013, 66, 246–257. [Google Scholar] [CrossRef] [PubMed]
  24. Phillips, O.A.; Udo, E.E.; Ali, A.A.; Al-Hassawi, N. Synthesis and antibacterial activity of 5-substituted oxazolidinones. Bioorg. Med. Chem. Lett. 2003, 11, 35–41. [Google Scholar] [CrossRef]
  25. Phillips, O.A.; Udo, E.E.; Ali, A.A.; Samuel, S.M. Synthesis and antibacterial activity of new N-linked 5-triazolylmethyl oxazolidinones. Bioorg. Med. Chem. 2005, 13, 4113–4123. [Google Scholar] [CrossRef] [PubMed]
  26. Phillips, O.A.; Udo, E.E.; Ali, A.A.; Samuel, S.M. Structure-antibacterial activity of arylcarbonyl- and arylsulfonyl-piperazine 5-triazolylmethyl oxazolidinones. Eur. J. Med. Chem. 2007, 42, 214–225. [Google Scholar] [CrossRef] [PubMed]
  27. Wang, X.J.; Wu, N.; Du, G.J.; Zhao, S.Q.; Yan, M.; Gu, L.Q. Synthesis and antibacterial activities of eperezolid analogs with glycinyl substitutions. Arch. Pharm. (Weinheim) 2009, 342, 377–385. [Google Scholar] [CrossRef] [PubMed]
  28. Brickner, S.J.; Hutchinson, D.K.; Barbachyn, M.R.; Manninen, P.R.; Ulanowicz, D.A.; Garmon, S.A.; Grega, K.C.; Hendges, S.K.; Toops, D.S.; Ford, C.W.; et al. Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. J. Med. Chem. 1996, 39, 673–679. [Google Scholar] [CrossRef] [PubMed]
  29. Clinical and Laboratory Standards Institute (CLSI). Susceptibility Testing of Mycobacteria, Nocaridae, and Other Aerobic Actinomycetes. Approved Standard, 2nd ed.; CLSI Document M24-A2; CLSI: Wayne, PA, USA, 2011. [Google Scholar]
  30. Wilson, D.N.; Harms, J.M.; Nierhaus, K.H.; Schlunzen, F.; Fucini, P. Species-specific antibiotic-ribosome interactions: Implications for drug development. Biol. Chem. 2005, 386, 1239–1252. [Google Scholar] [CrossRef] [PubMed]
  31. Phillips, O.A.; Udo, E.E.; Abdel-Hamid, M.E.; Varghese, R. Effects of varied substituents on the antibacterial activity of triazolylmethyl oxazolidinones. Arch. Pharm. (Weinheim) 2012, 345, 790–803. [Google Scholar] [CrossRef] [PubMed]
Scipharm 86 00042 g001 550
Figure 1. Chemical structure of oxazolidinone antibacterial agents.
Figure 1. Chemical structure of oxazolidinone antibacterial agents.
Scipharm 86 00042 g001
Scipharm 86 00042 sch001 550
Scheme 1. Synthesis of 5-(1H-1,2,3-triazolyl)methyl (D)- and (l)-alaninyl-oxazolidinone derivatives. (i) TFA/DCM, 0 °C-r.t.; (ii) CH3CN/DCM/tert-boc-(D)- or (l)-alanine/DCC/1-HOBT/TEA, r.t.; (iii) CH3CN/DCM/nitroaroyl acid/DCC/1-HOBT/TEA, or CH3CN/DCM/nitroheteroaroyl chloride, or nitroarylsulfonyl chloride/TEA, room temperature.
Scheme 1. Synthesis of 5-(1H-1,2,3-triazolyl)methyl (D)- and (l)-alaninyl-oxazolidinone derivatives. (i) TFA/DCM, 0 °C-r.t.; (ii) CH3CN/DCM/tert-boc-(D)- or (l)-alanine/DCC/1-HOBT/TEA, r.t.; (iii) CH3CN/DCM/nitroaroyl acid/DCC/1-HOBT/TEA, or CH3CN/DCM/nitroheteroaroyl chloride, or nitroarylsulfonyl chloride/TEA, room temperature.
Scipharm 86 00042 sch001
Table
Table 1. Antibacterial activity of D- and L-alaninyl triazolyl-oxazolidinone derivatives.
Table 1. Antibacterial activity of D- and L-alaninyl triazolyl-oxazolidinone derivatives.
Scipharm 86 00042 i001
CompoundRMIC (µg/mL) for
S. aureus ATCC25923S. epidermidis ATCC12228E. faecalis ATCC29212M. catarrhalis
15a (d)tert-butoxycarbonyl1688>16
15b (l)tert-butoxycarbonyl888>16
9a2-nitrobenzoyl84216
10a2-nitrobenzoyl8248
9b3-nitrobenzoyl2224
10b3-nitrobenzoyl2222
9c4-nitrobenzoyl4844
10c4-nitrobenzoyl4224
9d3,5-dinitrobenzoyl2222
10d3,5-dinitrobenzoyl2222
9e5-nitrofuran-2-carbonyl8248
10e5-nitrofuran-2-carbonyl2222
9f5-nitrothiopehene-2-carbonyl2222
10f5-nitrothiopehene-2-carbonyl2222
9g2-nitrobenezesufonyl1688>16
10g2-nitrobenezesufonyl168816
9h3-nitrobenezesufonyl>1641616
10h3-nitrobenezesufonyl16884
9i4-nitrobenezesufonyl>1641616
10i4-nitrobenezesufonyl>16244
9j2-aminobenzoyl .CF3CO2H4224
10j2-aminobenzoyl .CF3CO2H4244
9k3-aminobenzoyl .CF3CO2H8248
10k3-aminobenzoyl .CF3CO2H4224
9l4-aminobenzoyl .CF3CO2H4224
10l4-aminobenzoyl .CF3CO2H2224
Linezolid 2228

Share and Cite

MDPI and ACS Style

Phillips, O.A.; Udo, E.E.; D’silva, R.J. Structure-Antibacterial Activity Relationships of N-Substituted-(d-/l-Alaninyl) 1H-1,2,3-Triazolylmethyl Oxazolidinones. Sci. Pharm. 2018, 86, 42. https://doi.org/10.3390/scipharm86040042

AMA Style

Phillips OA, Udo EE, D’silva RJ. Structure-Antibacterial Activity Relationships of N-Substituted-(d-/l-Alaninyl) 1H-1,2,3-Triazolylmethyl Oxazolidinones. Scientia Pharmaceutica. 2018; 86(4):42. https://doi.org/10.3390/scipharm86040042

Chicago/Turabian Style

Phillips, Oludotun Adebayo, Edet Ekpenyong Udo, and Roselyn Jennifer D’silva. 2018. "Structure-Antibacterial Activity Relationships of N-Substituted-(d-/l-Alaninyl) 1H-1,2,3-Triazolylmethyl Oxazolidinones" Scientia Pharmaceutica 86, no. 4: 42. https://doi.org/10.3390/scipharm86040042

APA Style

Phillips, O. A., Udo, E. E., & D’silva, R. J. (2018). Structure-Antibacterial Activity Relationships of N-Substituted-(d-/l-Alaninyl) 1H-1,2,3-Triazolylmethyl Oxazolidinones. Scientia Pharmaceutica, 86(4), 42. https://doi.org/10.3390/scipharm86040042

Article Metrics

Back to TopTop